Lim PZ, Tunis SL, Edell WS, Jensik SE, Tohen M
Medication prescribing patterns for patients with bipolar I disorder in hospital settings: adherence to published practice guidelines. Bipolar Disord. 2001 Aug; 3(4):165-73.
Medication prescribing patterns for patients with bipolar I disorder in hospital settings: adherence to published practice guidelines.
Gonzalez R, Suppes T, Zeitzer J, McClung C, Tamminga C, Tohen M, Forero A, Dwivedi A, Alvarado A
International journal of bipolar disorders
The association between mood state and chronobiological characteristics in bipolar I disorder: a naturalistic, variable cluster analysis-based study. Int J Bipolar Disord. 2018 Feb 19; 6(1):5.
The association between mood state and chronobiological characteristics in bipolar I disorder: a naturalistic, variable cluster analysis-based study.
Green AI, Tohen M, Patel JK, Banov M, DuRand C, Berman I, Chang H, Zarate C, Posener J, Lee H, Dawson R, Richards C, Cole JO, Schatzberg AF
Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry. 2000 Jun; 157(6):982-6.
Clozapine in the treatment of refractory psychotic mania.
Tohen M, Sutton VK, Calabrese JR, Sachs GS, Bowden CL
Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorder. J Affect Disord. 2009 Jul; 116(1-2):43-50.
Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorder.
Strakowski SM, Hudson JI, Keck PE, Wilson DR, Frankenburg FR, Alpert JE, Teschke GC, Tohen M
Four cases of obstructive sleep apnea associated with treatment-resistant mania. J Clin Psychiatry. 1991 Apr; 52(4):156-8.
Four cases of obstructive sleep apnea associated with treatment-resistant mania.
Perkins DO, Johnson JL, Hamer RM, Zipursky RB, Keefe RS, Centorrhino F, Green AI, Glick IB, Kahn RS, Sharma T, Tohen M, McEvoy JP, Weiden PJ, Lieberman JA
Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res. 2006 Mar; 83(1):53-63.
Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode.
Prediction of outcome in mania by mood-congruent or mood-incongruent psychotic features. Am J Psychiatry. 1992 Nov; 149(11):1580-4.
Prediction of outcome in mania by mood-congruent or mood-incongruent psychotic features.
Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, Daniel DG, Petty F, Centorrino F, Wang R, Grundy SL, Greaney MG, Jacobs TG, David SR, Toma V
Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry. 1999 May; 156(5):702-9.
Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.
Tohen M, Castillo J, Baldessarini RJ, Zarate C, Kando JC
Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk. Am J Psychiatry. 1995 Mar; 152(3):413-8.
Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk.
Strakowski SM, Wilson DR, Tohen M, Woods BT, Douglass AW, Stoll AL
Structural brain abnormalities in first-episode mania. Biol Psychiatry. 1993 Apr 15-May 1; 33(8-9):602-9.
Structural brain abnormalities in first-episode mania.
Keck PE, McElroy SL, Richtand N, Tohen M
What makes a drug a primary mood stabilizer? Mol Psychiatry. 2002; 7 Suppl 1:S8-14.
What makes a drug a primary mood stabilizer?
Antipsychotic agents in the treatment of bipolar mania. Bipolar Disord. 2009 Jun; 11 Suppl 2:45-54.
Antipsychotic agents in the treatment of bipolar mania.
Baldessarini RJ, Salvatore P, Khalsa HM, Tohen M
Dissimilar morbidity following initial mania versus mixed-states in type-I bipolar disorder. J Affect Disord. 2010 Oct; 126(1-2):299-302.
Dissimilar morbidity following initial mania versus mixed-states in type-I bipolar disorder.
Severus WE, Lipkovich IA, Licht RW, Young AH, Greil W, Ketter T, Deberdt W, Tohen M
European psychiatry : the journal of the Association of European Psychiatrists
In search of optimal lithium levels and olanzapine doses in the long-term treatment of bipolar I disorder. A post-hoc analysis of the maintenance study by Tohen et al. 2005. Eur Psychiatry. 2010 Dec; 25(8):443-9.
In search of optimal lithium levels and olanzapine doses in the long-term treatment of bipolar I disorder. A post-hoc analysis of the maintenance study by Tohen et al. 2005.
Houston JP, Ketter TA, Case M, Bowden C, Degenhardt EK, Jamal HH, Tohen M
Early symptom change and prediction of subsequent remission with olanzapine augmentation in divalproex-resistant bipolar mixed episodes. J Psychiatr Res. 2011 Feb; 45(2):169-73.
Early symptom change and prediction of subsequent remission with olanzapine augmentation in divalproex-resistant bipolar mixed episodes.
Freedman R, Brown AS, Cannon TD, Druss BG, Earls FJ, Escobar J, Hurd YL, Lewis DA, López-Jaramillo C, Luby J, Mayberg HS, Moffitt TE, Oquendo M, Perlis RH, Pine DS, Rush AJ, Tamminga CA, Tohen M, Vieta E, Wisner KL, Xin Y
Can a Framework Be Established for the Safe Use of Ketamine? Am J Psychiatry. 2018 07 01; 175(7):587-589.
Can a Framework Be Established for the Safe Use of Ketamine?
Ascher-Svanum H, Zhu B, Faries D, Peng X, Kinon BJ, Tohen M
Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study. J Clin Psychiatry. 2008 Oct; 69(10):1580-8.
Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study.
Katagiri H, Takita Y, Tohen M, Higuchi T, Kanba S, Takahashi M
Efficacy and safety of olanzapine in the treatment of Japanese patients with bipolar I disorder in a current manic or mixed episode: a randomized, double-blind, placebo- and haloperidol-controlled study. J Affect Disord. 2012 Feb; 136(3):476-84.
Efficacy and safety of olanzapine in the treatment of Japanese patients with bipolar I disorder in a current manic or mixed episode: a randomized, double-blind, placebo- and haloperidol-controlled study.
Tohen M, Castillo J, Pope HG, Herbstein J
Concomitant use of valproate and carbamazepine in bipolar and schizoaffective disorders. J Clin Psychopharmacol. 1994 Feb; 14(1):67-70.
Concomitant use of valproate and carbamazepine in bipolar and schizoaffective disorders.
Vieta E, Panicali F, Goetz I, Reed C, Comes M, Tohen M
Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study. J Affect Disord. 2008 Feb; 106(1-2):63-72.
Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study.
Houston JP, Ahl J, Meyers AL, Kaiser CJ, Tohen M, Baldessarini RJ
Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex. J Clin Psychiatry. 2006 Aug; 67(8):1246-52.
Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex.
Kryzhanovskaya L, Schulz SC, McDougle C, Frazier J, Dittmann R, Robertson-Plouch C, Bauer T, Xu W, Wang W, Carlson J, Tohen M
Journal of the American Academy of Child and Adolescent Psychiatry
Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009 Jan; 48(1):60-70.
Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.
Tohen M, Case M, Trivedi MH, Thase ME, Burke SJ, Durell TM
Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J Clin Psychiatry. 2010 Apr; 71(4):451-62.
Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies.
Degenhardt EK, Gatz JL, Jacob J, Tohen M
Predictors of relapse or recurrence in bipolar I disorder. J Affect Disord. 2012 Feb; 136(3):733-9.
Predictors of relapse or recurrence in bipolar I disorder.
Tohen M, Castillo J, Cole JO, Miller MG, de los Heros R, Farrer RJ
Thrombocytopenia associated with carbamazepine: a case series. J Clin Psychiatry. 1991 Dec; 52(12):496-8.
Thrombocytopenia associated with carbamazepine: a case series.
Shi L, Juarez R, Hackworth J, Edgell ET, Haro JM, Vieta E, Tohen MF
Open-label olanzapine treatment in bipolar I disorder: clinical and work functional outcomes. Curr Med Res Opin. 2006 May; 22(5):961-6.
Open-label olanzapine treatment in bipolar I disorder: clinical and work functional outcomes.
Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, McEvoy JP, Perkins DO, Rothschild AJ, Sharma T, Tohen MF, Woolson S, Zipursky RB
Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res. 2006 Sep; 86(1-3):234-43.
Olanzapine and haloperidol in first episode psychosis: two-year data.
World psychiatry : official journal of the World Psychiatric Association (WPA)
Conflicts of interest and the credibility of psychiatric research. World Psychiatry. 2007 Feb; 6(1):33-4.
Conflicts of interest and the credibility of psychiatric research.
Collaborations between academic psychiatry and the pharmaceutical industry: a perspective from industry. Epidemiol Psichiatr Soc. 2007 Jul-Sep; 16(3):197-8.
Collaborations between academic psychiatry and the pharmaceutical industry: a perspective from industry.
First-episode schizophreniform disorder: comparisons with first-episode schizophrenia. Schizophr Res. 2000 Nov 30; 46(1):31-4.
First-episode schizophreniform disorder: comparisons with first-episode schizophrenia.
Miller TJ, Zipursky RB, Perkins D, Addington J, Woods SW, Hawkins KA, Hoffman R, Preda A, Epstein I, Addington D, Lindborg S, Marquez E, Tohen M, Breier A, McGlashan TH
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophr Res. 2003 May 01; 61(1):19-30.
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample.
Nestsiarovich A, Mazurie AJ, Hurwitz NG, Kerner B, Nelson SJ, Crisanti AS, Tohen M, Krall RL, Perkins DJ, Lambert CG
Comprehensive comparison of monotherapies for psychiatric hospitalization risk in bipolar disorders. Bipolar Disord. 2018 12; 20(8):761-771.
Comprehensive comparison of monotherapies for psychiatric hospitalization risk in bipolar disorders.
Novick D, Reed C, Haro JM, Gonzalez-Pinto A, Perrin E, Aguado J, Tohen M
International clinical psychopharmacology
Comparison of olanzapine and risperidone in the EMBLEM Study: translation of randomized controlled trial findings into clinical practice. Int Clin Psychopharmacol. 2010 Sep; 25(5):257-63.
Comparison of olanzapine and risperidone in the EMBLEM Study: translation of randomized controlled trial findings into clinical practice.
Dion GL, Tohen M, Anthony WA, Waternaux CS
Symptoms and functioning of patients with bipolar disorder six months after hospitalization. Hosp Community Psychiatry. 1988 Jun; 39(6):652-7.
Symptoms and functioning of patients with bipolar disorder six months after hospitalization.
Zarate CA, Tohen M, Baraibar G, Kando JC, Mirin J
Prescribing trends of antidepressants in bipolar depression. J Clin Psychiatry. 1995 Jun; 56(6):260-4.
Prescribing trends of antidepressants in bipolar depression.
Baldessarini RJ, Salvatore P, Khalsa HK, Imaz-Etxeberria H, Gonzalez-Pinto A, Tohen M
Episode cycles with increasing recurrences in first-episode bipolar-I disorder patients. J Affect Disord. 2012 Jan; 136(1-2):149-154.
Episode cycles with increasing recurrences in first-episode bipolar-I disorder patients.
Olanzapine in schizophrenia and affective disorders. Drug Saf. 2012 Dec 01; 35(12):1185-6; author reply 1186.
Olanzapine in schizophrenia and affective disorders.
Methodologies to avoid the enrollment of ineligible patients in clinical trials. J Clin Psychiatry. 2012 Nov; 73(11):1426-7.
Methodologies to avoid the enrollment of ineligible patients in clinical trials.
Suppes T, Brown E, Schuh LM, Baker RW, Tohen M
Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-week data. J Affect Disord. 2005 Dec; 89(1-3):69-77.
Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-week data.
Outcome in Mania. A 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry. 1990 Dec; 47(12):1106-11.
Outcome in Mania. A 4-year prospective follow-up of 75 patients utilizing survival analysis.
Thompson PM, Bartzokis G, Hayashi KM, Klunder AD, Lu PH, Edwards N, Hong MS, Yu M, Geaga JA, Toga AW, Charles C, Perkins DO, McEvoy J, Hamer RM, Tohen M, Tollefson GD, Lieberman JA
Time-lapse mapping of cortical changes in schizophrenia with different treatments. Cereb Cortex. 2009 May; 19(5):1107-23.
Time-lapse mapping of cortical changes in schizophrenia with different treatments.
Dubé S, Tollefson GD, Thase ME, Briggs SD, Van Campen LE, Case M, Tohen M
Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression. Bipolar Disord. 2007 Sep; 9(6):618-27.
Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression.
Stoll AL, Mayer PV, Kolbrener M, Goldstein E, Suplit B, Lucier J, Cohen BM, Tohen M
Antidepressant-associated mania: a controlled comparison with spontaneous mania. Am J Psychiatry. 1994 Nov; 151(11):1642-5.
Antidepressant-associated mania: a controlled comparison with spontaneous mania.
Khalsa HK, Baldessarini RJ, Tohen M, Salvatore P
Aggression among 216 patients with a first-psychotic episode of bipolar I disorder. Int J Bipolar Disord. 2018 Aug 11; 6(1):18.
Aggression among 216 patients with a first-psychotic episode of bipolar I disorder.
Brown E, Dunner DL, McElroy SL, Keck PE, Adams DH, Degenhardt E, Tohen M, Houston JP
The international journal of neuropsychopharmacology
Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression. Int J Neuropsychopharmacol. 2009 Jul; 12(6):773-82.
Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression.
Tohen M, Frank E, Bowden CL, Colom F, Ghaemi SN, Yatham LN, Malhi GS, Calabrese JR, Nolen WA, Vieta E, Kapczinski F, Goodwin GM, Suppes T, Sachs GS, Chengappa KR, Grunze H, Mitchell PB, Kanba S, Berk M
The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord. 2009 Aug; 11(5):453-73.
The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders.
Kando JC, Tohen M, Castillo J, Centorrino F
Concurrent use of clozapine and valproate in affective and psychotic disorders. J Clin Psychiatry. 1994 Jun; 55(6):255-7.
Concurrent use of clozapine and valproate in affective and psychotic disorders.
Diagnosis and management of bipolar II disorder. Compr Ther. 1994; 20(2):121-4.
Diagnosis and management of bipolar II disorder.
Hawkins KA, Keefe RS, Christensen BK, Addington J, Woods SW, Callahan J, Zipursky RB, Perkins DO, Tohen M, Breier A, McGlashan TH
Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study. Schizophr Res. 2008 Oct; 105(1-3):1-9.
Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study.
Salvatore P, Baldessarini RJ, Tohen M, Khalsa HM, Sanchez-Toledo JP, Zarate CA, Vieta E, Maggini C
McLean-Harvard International First-Episode Project: two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients. J Clin Psychiatry. 2009 Apr; 70(4):458-66.
McLean-Harvard International First-Episode Project: two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients.
Novick D, Gonzalez-Pinto A, Haro JM, Bertsch J, Reed C, Perrin E, Tohen M
Translation of randomised controlled trial findings into clinical practice: comparison of olanzapine and valproate in the EMBLEM study. Pharmacopsychiatry. 2009 Jul; 42(4):145-52.
Translation of randomised controlled trial findings into clinical practice: comparison of olanzapine and valproate in the EMBLEM study.
Tamayo JM, Zarate CA, Vieta E, Vázquez G, Tohen M
Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2010 Jul; 13(6):813-32.
Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis.
Is there a long-term protective effect of mood-altering agents in unipolar depressive disorder? Psychopharmacol Ser. 1988; 5:130-9.
Is there a long-term protective effect of mood-altering agents in unipolar depressive disorder?
Canadian journal of psychiatry. Revue canadienne de psychiatrie
Preparation for the certification examination. Can J Psychiatry. 1983 Oct; 28(6):471-4.
Preparation for the certification examination.
Yaramala SR, McElroy SL, Geske J, Winham S, Gao K, Reilly-Harrington NA, Ketter TA, Deckersbach T, Kinrys G, Kamali M, Sylvia LG, McInnis MG, Friedman ES, Thase ME, Kocsis JH, Tohen M, Calabrese JR, Bowden CL, Shelton RC, Nierenberg AA, Bobo WV
The impact of binge eating behavior on lithium- and quetiapine-associated changes in body weight, body mass index, and waist circumference during 6 months of treatment: Findings from the bipolar CHOICE study. J Affect Disord. 2020 04 01; 266:772-781.
The impact of binge eating behavior on lithium- and quetiapine-associated changes in body weight, body mass index, and waist circumference during 6 months of treatment: Findings from the bipolar CHOICE study.
Baldessarini RJ, Undurraga J, Vázquez GH, Tondo L, Salvatore P, Ha K, Khalsa HM, Lepri B, Ha TH, Chang JS, Tohen M, Vieta E
Predominant recurrence polarity among 928 adult international bipolar I disorder patients. Acta Psychiatr Scand. 2012 Apr; 125(4):293-302.
Predominant recurrence polarity among 928 adult international bipolar I disorder patients.
Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA, Bowden CL, Sachs GS, Kupfer DJ, Ghaemi SN, Feldman PD, Risser RC, Evans AR, Calabrese JR
The British journal of psychiatry : the journal of mental science
Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry. 2004 Apr; 184:337-45.
Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone.
Keck PE, Corya SA, Altshuler LL, Ketter TA, McElroy SL, Case M, Briggs SD, Tohen M
Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. J Clin Psychiatry. 2005 May; 66(5):611-6.
Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression.
Renshaw PF, Yurgelun-Todd DA, Tohen M, Gruber S, Cohen BM
Temporal lobe proton magnetic resonance spectroscopy of patients with first-episode psychosis. Am J Psychiatry. 1995 Mar; 152(3):444-6.
Temporal lobe proton magnetic resonance spectroscopy of patients with first-episode psychosis.
Pope HG, Jonas JM, Hudson JI, Cohen BM, Tohen M
An empirical study of psychosis in borderline personality disorder. Am J Psychiatry. 1985 Nov; 142(11):1285-90.
An empirical study of psychosis in borderline personality disorder.
Suppes T, Baldessarini RJ, Faedda GL, Tondo L, Tohen M
Discontinuation of maintenance treatment in bipolar disorder: risks and implications. Harv Rev Psychiatry. 1993 Sep-Oct; 1(3):131-44.
Discontinuation of maintenance treatment in bipolar disorder: risks and implications.
First-episode mania in late life. Am J Psychiatry. 1994 Jan; 151(1):130-2.
Tohen M, Vieta E, Goodwin GM, Sun B, Amsterdam JD, Banov M, Shekhar A, Aaronson ST, Bardenstein L, Grecu-Gabos I, Tochilov V, Prelipceanu D, Oliff HS, Kryzhanovskaya L, Bowden C
Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. J Clin Psychiatry. 2008 Nov; 69(11):1776-89.
Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study.
Frankenburg FR, Tohen M, Cohen BM, Lipinski JF
Long-term response to carbamazepine: a retrospective study. J Clin Psychopharmacol. 1988 Apr; 8(2):130-2.
Long-term response to carbamazepine: a retrospective study.
Behrendt-Møller I, Madsen T, Sørensen HJ, Sylvia L, Friedman ES, Shelton RC, Bowden CL, Calabrese JR, McElroy SL, Ketter TA, Reilly-Harrington NA, Gao K, Thase M, V Bobo W, Tohen M, McInnis M, Kamali M, Kocsis JH, Deckersbach T, Köhler-Forsberg O, Nierenberg AA
Patterns of changes in bipolar depressive symptoms revealed by trajectory analysis among 482 patients with bipolar disorder. Bipolar Disord. 2019 06; 21(4):350-360.
Patterns of changes in bipolar depressive symptoms revealed by trajectory analysis among 482 patients with bipolar disorder.
Substance abuse and the chronically mentally ill: a description of dual diagnosis treatment services in a psychiatric hospital. Community Ment Health J. 1995 Jun; 31(3):265-77.
Substance abuse and the chronically mentally ill: a description of dual diagnosis treatment services in a psychiatric hospital.
Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Risser R, Zhang F, Toma V, Francis J, Tollefson GD, Breier A
Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry. 2000 Sep; 57(9):841-9.
Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.
Sachs GS, Lafer B, Stoll AL, Banov M, Thibault AB, Tohen M, Rosenbaum JF
A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry. 1994 Sep; 55(9):391-3.
A double-blind trial of bupropion versus desipramine for bipolar depression.
Unipolar mania reconsidered: evidence from an elderly cohort. Br J Psychiatry. 1994 Apr; 164(4):547-9.
Unipolar mania reconsidered: evidence from an elderly cohort.
Strakowski SM, Stoll AL, Tohen M, Faedda GL, Goodwin DC
The Tridimensional Personality Questionnaire as a predictor of six-month outcome in first episode mania. Psychiatry Res. 1993 Jul; 48(1):1-8.
The Tridimensional Personality Questionnaire as a predictor of six-month outcome in first episode mania.
Cycling into depression from a first episode of mania: a case-comparison study. Am J Psychiatry. 2001 Sep; 158(9):1524-6.
Cycling into depression from a first episode of mania: a case-comparison study.
Baker RW, Milton DR, Stauffer VL, Gelenberg A, Tohen M
Placebo-controlled trials do not find association of olanzapine with exacerbation of bipolar mania. J Affect Disord. 2003 Jan; 73(1-2):147-53.
Placebo-controlled trials do not find association of olanzapine with exacerbation of bipolar mania.
Baldessarini RJ, Hennen J, Wilson M, Calabrese J, Chengappa R, Keck PE, McElroy SL, Sachs G, Vieta E, Welge JA, Yatham LN, Zarate CA, Baker RW, Tohen M
Olanzapine versus placebo in acute mania: treatment responses in subgroups. J Clin Psychopharmacol. 2003 Aug; 23(4):370-6.
Olanzapine versus placebo in acute mania: treatment responses in subgroups.
Baker RW, Brown E, Akiskal HS, Calabrese JR, Ketter TA, Schuh LM, Trzepacz PT, Watkin JG, Tohen M
Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania. Br J Psychiatry. 2004 Dec; 185:472-8.
Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania.
Williamson D, Brown E, Perlis RH, Ahl J, Baker RW, Tohen M
Clinical relevance of depressive symptom improvement in bipolar I depressed patients. J Affect Disord. 2006 Jun; 92(2-3):261-6.
Clinical relevance of depressive symptom improvement in bipolar I depressed patients.
High risk of eosinophilia in women treated with clozapine. J Clin Psychiatry. 1993 Dec; 54(12):466-9.
High risk of eosinophilia in women treated with clozapine.
Faedda GL, Tondo L, Baldessarini RJ, Suppes T, Tohen M
Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry. 1993 Jun; 50(6):448-55.
Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders.
Predicting the course and outcome of bipolar disorder: a review. Eur Psychiatry. 2010 Oct; 25(6):328-33.
Predicting the course and outcome of bipolar disorder: a review.
Kinrys G, Bowden CL, Nierenberg AA, Hearing CM, Gold AK, Rabideau DJ, Sylvia LG, Gao K, Kamali M, Bobo WV, Tohen M, Deckersbach T, McElroy SL, Ketter TA, Shelton RC, Friedman ES, Calabrese JR, McInnis MG, Kocsis J, Thase ME, Singh V, Reilly-Harrington NA
Comorbid anxiety in bipolar CHOICE: Insights from the bipolar inventory of symptoms scale. J Affect Disord. 2019 03 01; 246:126-131.
Comorbid anxiety in bipolar CHOICE: Insights from the bipolar inventory of symptoms scale.
Strakowski SM, Tohen M, Stoll AL, Faedda GL, Goodwin DC
Comorbidity in mania at first hospitalization. Am J Psychiatry. 1992 Apr; 149(4):554-6.
Comorbidity in mania at first hospitalization.
Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C, Tollefson GD
Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry. 1999 Jan; 156(1):79-87.
Olanzapine versus haloperidol treatment in first-episode psychosis.
Functional impairment and cognition in bipolar disorder. Psychiatr Q. 2000; 71(4):309-29.
Functional impairment and cognition in bipolar disorder.
Increasing frequency of the diagnosis of obsessive-compulsive disorder. Am J Psychiatry. 1992 May; 149(5):638-40.
Increasing frequency of the diagnosis of obsessive-compulsive disorder.
Tohen M, Chengappa KN, Suppes T, Zarate CA, Calabrese JR, Bowden CL, Sachs GS, Kupfer DJ, Baker RW, Risser RC, Keeter EL, Feldman PD, Tollefson GD, Breier A
Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002 Jan; 59(1):62-9.
Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy.
Strakowski SM, Johnson JL, Delbello MP, Hamer RM, Green AI, Tohen M, Lieberman JA, Glick I, Patel JK
Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. Schizophr Res. 2005 Oct 15; 78(2-3):161-9.
Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode.
Journal of psychopharmacology (Oxford, England)
Olanzapine - relapse prevention following mania. J Psychopharmacol. 2006 Mar; 20(2 Suppl):31-8.
Olanzapine - relapse prevention following mania.
Lipinski JF, Cohen BM, Frankenburg F, Tohen M, Waternaux C, Altesman R, Jones B, Harris P
Open trial of S-adenosylmethionine for treatment of depression. Am J Psychiatry. 1984 Mar; 141(3):448-50.
Open trial of S-adenosylmethionine for treatment of depression.
Popli AP, Kando JC, Pillay SS, Tohen M, Cole JO
Occurrence of seizures related to psychotropic medication among psychiatric inpatients. Psychiatr Serv. 1995 May; 46(5):486-8.
Occurrence of seizures related to psychotropic medication among psychiatric inpatients.
Zarate CA, Kando JC, Tohen M, Weiss MK, Cole JO
Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? J Clin Psychiatry. 1996 Feb; 57(2):67-71.
Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline?
Nestsiarovich A, Kerner B, Mazurie AJ, Cannon DC, Hurwitz NG, Zhu Y, Nelson SJ, Oprea TI, Unruh ML, Crisanti AS, Tohen M, Perkins DJ, Lambert CG
Comparison of 71 bipolar disorder pharmacotherapies for kidney disorder risk: The potential hazards of polypharmacy. J Affect Disord. 2019 06 01; 252:201-211.
Comparison of 71 bipolar disorder pharmacotherapies for kidney disorder risk: The potential hazards of polypharmacy.
Chen M, Fitzgerald HM, Madera JJ, Tohen M
Functional outcome assessment in bipolar disorder: A systematic literature review. Bipolar Disord. 2019 05; 21(3):194-214.
Functional outcome assessment in bipolar disorder: A systematic literature review.
Electroconvulsive therapy electrode placement for bipolar state-related targeted engagement. Int J Bipolar Disord. 2019 May 04; 7(1):11.
Electroconvulsive therapy electrode placement for bipolar state-related targeted engagement.
Harvard T.H. Chan School of Public Health
Nolen WA, Licht RW, Young AH, Malhi GS, Tohen M, Vieta E, Kupka RW, Zarate C, Nielsen RE, Baldessarini RJ, Severus E
What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD/IGSLI Task Force on treatment with lithium. Bipolar Disord. 2019 08; 21(5):394-409.
What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD/IGSLI Task Force on treatment with lithium.
Köhler-Forsberg O, Sylvia LG, Bowden CL, Calabrese JR, Thase ME, Shelton RC, McInnis M, Tohen M, Kocsis JH, Ketter TA, Friedman ES, Deckersbach T, Ostacher MJ, Iosifescu DV, McElroy S, Nierenberg AA
Correlation between white blood cell count and mood-stabilising treatment response in two bipolar disorder trials. Acta Neuropsychiatr. 2019 Aug; 31(4):230-234.
Correlation between white blood cell count and mood-stabilising treatment response in two bipolar disorder trials.
Kerner B, Crisanti AS, DeShaw JL, Ho JG, Jordan K, Krall RL, Kuntz MJ, Mazurie AJ, Nestsiarovich A, Perkins DJ, Schroeter QL, Smith AN, Tohen M, Volesky E, Zhu Y, Lambert CG
Preferences of Information Dissemination on Treatment for Bipolar Disorder: Patient-Centered Focus Group Study. JMIR Ment Health. 2019 Jun 25; 6(6):e12848.
Preferences of Information Dissemination on Treatment for Bipolar Disorder: Patient-Centered Focus Group Study.
Fung VC, Overhage LN, Sylvia LG, Reilly-Harrington NA, Kamali M, Gao K, Shelton RC, Ketter TA, Bobo WV, Thase ME, Calabrese JR, Tohen M, Deckersbach T, Nierenberg AA
Complex polypharmacy in bipolar disorder: Side effect burden, adherence, and response predictors. J Affect Disord. 2019 10 01; 257:17-22.
Complex polypharmacy in bipolar disorder: Side effect burden, adherence, and response predictors.
Kamali M, Reilly-Harrington NA, Chang WC, McInnis M, McElroy SL, Ketter TA, Shelton RC, Deckersbach T, Tohen M, Kocsis JH, Calabrese JR, Gao K, Thase ME, Bowden CL, Kinrys G, Bobo WV, Brody BD, Sylvia LG, Rabideau DJ, Nierenberg AA
Bipolar depression and suicidal ideation: Moderators and mediators of a complex relationship. J Affect Disord. 2019 12 01; 259:164-172.
Bipolar depression and suicidal ideation: Moderators and mediators of a complex relationship.
Faedda GL, Baldessarini RJ, Marangoni C, Bechdolf A, Berk M, Birmaher B, Conus P, DelBello MP, Duffy AC, Hillegers MHJ, Pfennig A, Post RM, Preisig M, Ratheesh A, Salvatore P, Tohen M, Vázquez GH, Vieta E, Yatham LN, Youngstrom EA, Van Meter A, Correll CU
An International Society of Bipolar Disorders task force report: Precursors and prodromes of bipolar disorder. Bipolar Disord. 2019 12; 21(8):720-740.
An International Society of Bipolar Disorders task force report: Precursors and prodromes of bipolar disorder.
Earley WR, Burgess MV, Khan B, Rekeda L, Suppes T, Tohen M, Calabrese JR
Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study. Bipolar Disord. 2020 06; 22(4):372-384.
Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study.
Nestsiarovich A, Kerner B, Mazurie AJ, Cannon DC, Hurwitz NG, Zhu Y, Nelson SJ, Oprea TI, Crisanti AS, Tohen M, Perkins DJ, Lambert CG
Diabetes mellitus risk for 102 drugs and drug combinations used in patients with bipolar disorder. Psychoneuroendocrinology. 2020 02; 112:104511.
Diabetes mellitus risk for 102 drugs and drug combinations used in patients with bipolar disorder.
Fountoulakis KN, Yatham LN, Grunze H, Vieta E, Young AH, Blier P, Tohen M, Kasper S, Moeller HJ
The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder. Int J Neuropsychopharmacol. 2020 04 23; 23(4):230-256.
The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder.
Caroff SN, Citrome L, Meyer J, Sajatovic M, Goldberg JF, Jain R, Lundt L, Lindenmayer JP, McEvoy JP, McIntyre RS, Tohen M, Ketter TA
A Modified Delphi Consensus Study of the Screening, Diagnosis, and Treatment of Tardive Dyskinesia. J Clin Psychiatry. 2020 Jan 28; 81(2).
A Modified Delphi Consensus Study of the Screening, Diagnosis, and Treatment of Tardive Dyskinesia.
Miller J, Atala R, Sarangarm D, Tohen M, Sharma S, Bhatt S, Khafaja M, Kroth PJ, Cruz M
Methamphetamine Abuse Trends in Psychiatric Emergency Services: A Retrospective Analysis Using Big Data. Community Ment Health J. 2020 07; 56(5):959-962.
Methamphetamine Abuse Trends in Psychiatric Emergency Services: A Retrospective Analysis Using Big Data.
Köhler-Forsberg O, Sylvia LG, Ruberto VL, Kuperberg M, Shannon AP, Fung V, Overhage L, Calabrese JR, Thase M, Bowden CL, Shelton RC, McInnis M, Deckersbach T, Tohen M, Kocsis JH, Ketter TA, Friedman ES, Iosifescu DV, McElroy S, Ostacher MJ, Nierenberg AA
Familial severe psychiatric history in bipolar disorder and correlation with disease severity and treatment response. J Affect Disord. 2020 08 01; 273:131-137.
Familial severe psychiatric history in bipolar disorder and correlation with disease severity and treatment response.
Bustillo JR, Upston J, Mayer EG, Jones T, Maudsley AA, Gasparovic C, Tohen M, Lenroot R
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Glutamatergic hypo-function in the left superior and middle temporal gyri in early schizophrenia: a data-driven three-dimensional proton spectroscopic imaging study. Neuropsychopharmacology. 2020 10; 45(11):1851-1859.
Glutamatergic hypo-function in the left superior and middle temporal gyri in early schizophrenia: a data-driven three-dimensional proton spectroscopic imaging study.
Tohen M, Goldberg JF, Hassoun Y, Sureddi S
Identifying Profiles of Patients With Bipolar I Disorder Who Would Benefit From Maintenance Therapy With a Long-Acting Injectable Antipsychotic. J Clin Psychiatry. 2020 06 16; 81(4).
Identifying Profiles of Patients With Bipolar I Disorder Who Would Benefit From Maintenance Therapy With a Long-Acting Injectable Antipsychotic.
Köhler-Forsberg O, Sylvia LG, Fung V, Overhage L, Thase M, Calabrese JR, Deckersbach T, Tohen M, Bowden CL, McInnis M, Kocsis JH, Friedman ES, Ketter TA, McElroy SL, Shelton RC, Ostacher MJ, Iosifescu DV, Nierenberg AA
Adjunctive antidepressant treatment among 763 outpatients with bipolar disorder: Findings from the Bipolar CHOICE and LiTMUS trials. Depress Anxiety. 2021 02; 38(2):114-123.
Adjunctive antidepressant treatment among 763 outpatients with bipolar disorder: Findings from the Bipolar CHOICE and LiTMUS trials.
Bessonova L, Ogden K, Doane MJ, O'Sullivan AK, Tohen M
ClinicoEconomics and outcomes research : CEOR
The Economic Burden of Bipolar Disorder in the United States: A Systematic Literature Review. Clinicoecon Outcomes Res. 2020; 12:481-497.
The Economic Burden of Bipolar Disorder in the United States: A Systematic Literature Review.
Sanchez C, Grzenda A, Varias A, Widge AS, Carpenter LL, McDonald WM, Nemeroff CB, Kalin NH, Martin G, Tohen M, Filippou-Frye M, Ramsey D, Linos E, Mangurian C, Rodriguez CI
Social media recruitment for mental health research: A systematic review. Compr Psychiatry. 2020 11; 103:152197.
Social media recruitment for mental health research: A systematic review.
Salvatore P, Khalsa HK, Tohen M, Baldessarini RJ
Long-term morbidity in major affective and schizoaffective disorders following hospitalization in first psychotic episodes. Acta Psychiatr Scand. 2021 01; 143(1):50-60.
Long-term morbidity in major affective and schizoaffective disorders following hospitalization in first psychotic episodes.
Patel M, Jain R, Tohen M, Maletic V, Earley WR, Yatham LN
Efficacy of cariprazine in bipolar I depression across patient characteristics: a post hoc analysis of pooled randomized, placebo-controlled studies. Int Clin Psychopharmacol. 2021 03 01; 36(2):76-83.
Efficacy of cariprazine in bipolar I depression across patient characteristics: a post hoc analysis of pooled randomized, placebo-controlled studies.
Verdolini N, Hidalgo-Mazzei D, Del Matto L, Muscas M, Pacchiarotti I, Murru A, Samalin L, Aedo A, Tohen M, Grunze H, Young AH, Carvalho AF, Vieta E
Long-term treatment of bipolar disorder type I: A systematic and critical review of clinical guidelines with derived practice algorithms. Bipolar Disord. 2021 06; 23(4):324-340.
Long-term treatment of bipolar disorder type I: A systematic and critical review of clinical guidelines with derived practice algorithms.
Kraguljac NV, McDonald WM, Widge AS, Rodriguez CI, Tohen M, Nemeroff CB
Neuroimaging Biomarkers in Schizophrenia. Am J Psychiatry. 2021 06; 178(6):509-521.
Neuroimaging Biomarkers in Schizophrenia.
Interpreting the Findings of a Meta-analysis of Psychosocial Interventions in Bipolar Disorder. JAMA Psychiatry. 2021 04 01; 78(4):447-448.
Interpreting the Findings of a Meta-analysis of Psychosocial Interventions in Bipolar Disorder.
Doane MJ, Ogden K, Bessonova L, O'Sullivan AK, Tohen M
Real-World Patterns of Utilization and Costs Associated with Second-Generation Oral Antipsychotic Medication for the Treatment of Bipolar Disorder: A Literature Review. Neuropsychiatr Dis Treat. 2021; 17:515-531.
Real-World Patterns of Utilization and Costs Associated with Second-Generation Oral Antipsychotic Medication for the Treatment of Bipolar Disorder: A Literature Review.
Nestsiarovich A, Kumar P, Lauve NR, Hurwitz NG, Mazurie AJ, Cannon DC, Zhu Y, Nelson SJ, Crisanti AS, Kerner B, Tohen M, Perkins DJ, Lambert CG
Using Machine Learning Imputed Outcomes to Assess Drug-Dependent Risk of Self-Harm in Patients with Bipolar Disorder: A Comparative Effectiveness Study. JMIR Ment Health. 2021 Apr 21; 8(4):e24522.
Using Machine Learning Imputed Outcomes to Assess Drug-Dependent Risk of Self-Harm in Patients with Bipolar Disorder: A Comparative Effectiveness Study.
Ramírez-Bermúdez J, Marrufo-Melendez O, Berlanga-Flores C, Guadamuz A, Atriano C, Carrillo-Mezo R, Alvarado P, Favila R, Taboada J, Rios C, Yoldi-Negrete M, Ruiz-Garcia R, Tohen M
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
White Matter Abnormalities in Late Onset First Episode Mania: A Diffusion Tensor Imaging Study. Am J Geriatr Psychiatry. 2021 12; 29(12):1225-1236.
White Matter Abnormalities in Late Onset First Episode Mania: A Diffusion Tensor Imaging Study.
Cariprazine as a Treatment Option for Depressive Episodes Associated with Bipolar 1 Disorder in Adults: An Evidence-Based Review of Recent Data. Drug Des Devel Ther. 2021; 15:2005-2012.
Cariprazine as a Treatment Option for Depressive Episodes Associated with Bipolar 1 Disorder in Adults: An Evidence-Based Review of Recent Data.
Vieta E, Calabrese JR, Whelan J, Tohen M, Earley WR
The efficacy of cariprazine on function in patients with bipolar depression: a post hoc analysis of a randomized controlled trial. Curr Med Res Opin. 2021 09; 37(9):1635-1643.
The efficacy of cariprazine on function in patients with bipolar depression: a post hoc analysis of a randomized controlled trial.
Friedman BR, Durán DK, Nestsiarovich A, Tohen M, Lenroot RK, Bustillo JR, Crisanti AS
Characteristics of Hispanics Referred to Coordinated Specialty Care for First-Episode Psychosis and Factors Associated With Enrollment. Psychiatr Serv. 2021 12 01; 72(12):1407-1414.
Characteristics of Hispanics Referred to Coordinated Specialty Care for First-Episode Psychosis and Factors Associated With Enrollment.
Bowden CL, Priesmeyer R, Tohen M, Singh V, Calabrese JR, Ketter T, Nierenberg A, Thase ME, Siegel G, Siegel LH, Mintz J, El-Mallakh RS, McElroy SL, Martinez M
Development of a Patient-Centered Software System to Facilitate Effective Management of Bipolar Disorder. Psychopharmacol Bull. 2021 Mar 16; 51(2):8-19.
Development of a Patient-Centered Software System to Facilitate Effective Management of Bipolar Disorder.
Kamali M, Pegg S, Janos JA, Bobo WV, Brody B, Gao K, Ketter TA, McElroy SL, McInnis MG, Rabideau DJ, Reilly-Harrington NA, Shelton RC, Sylvia LG, Tohen M, Nierenberg A
Illness stage and predominant polarity in bipolar disorder: Correlation with burden of illness and moderation of treatment outcome. J Psychiatr Res. 2021 08; 140:205-213.
Illness stage and predominant polarity in bipolar disorder: Correlation with burden of illness and moderation of treatment outcome.
Bustillo JR, Mayer EG, Upston J, Jones T, Garcia C, Sheriff S, Maudsley A, Tohen M, Gasparovic C, Lenroot R
Increased Glutamate Plus Glutamine in the Right Middle Cingulate in Early Schizophrenia but Not in Bipolar Psychosis: A Whole Brain 1H-MRS Study. Front Psychiatry. 2021; 12:660850.
Increased Glutamate Plus Glutamine in the Right Middle Cingulate in Early Schizophrenia but Not in Bipolar Psychosis: A Whole Brain 1H-MRS Study.
Kupka R, Duffy A, Scott J, Almeida J, Balanzá-Martínez V, Birmaher B, Bond DJ, Brietzke E, Chendo I, Frey BN, Grande I, Hafeman D, Hajek T, Hillegers M, Kauer-Sant'Anna M, Mansur RB, van der Markt A, Post R, Tohen M, Tremain H, Vazquez G, Vieta E, Yatham LN, Berk M, Alda M, Kapczinski F
Consensus on nomenclature for clinical staging models in bipolar disorder: A narrative review from the International Society for Bipolar Disorders (ISBD) Staging Task Force. Bipolar Disord. 2021 11; 23(7):659-678.
Consensus on nomenclature for clinical staging models in bipolar disorder: A narrative review from the International Society for Bipolar Disorders (ISBD) Staging Task Force.
Nestsiarovich A, Gaudiot CES, Baldessarini RJ, Vieta E, Zhu Y, Tohen M
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
Preventing new episodes of bipolar disorder in adults: Systematic review and meta-analysis of randomized controlled trials. Eur Neuropsychopharmacol. 2022 01; 54:75-89.
Preventing new episodes of bipolar disorder in adults: Systematic review and meta-analysis of randomized controlled trials.
Köhler-Forsberg O, Sloth KH, Sylvia LG, Thase M, Calabrese JR, Tohen M, Bowden CL, McInnis M, Kocsis JH, Friedman ES, Ketter TA, McElroy SL, Shelton RC, Iosifescu DV, Ostacher MJ, Nierenberg AA
Response and remission rates during 24 weeks of mood-stabilizing treatment for bipolar depression depending on early non-response. Psychiatry Res. 2021 11; 305:114194.
Response and remission rates during 24 weeks of mood-stabilizing treatment for bipolar depression depending on early non-response.
Salvatore P, Baldessarini RJ, Khalsa HK, Tohen M
Prodromal features in first-psychotic episodes of major affective and schizoaffective disorders. J Affect Disord. 2021 12 01; 295:1251-1258.
Prodromal features in first-psychotic episodes of major affective and schizoaffective disorders.
Fountoulakis KN, Karakatsoulis G, Abraham S, Adorjan K, Ahmed HU, Alarcón RD, Arai K, Auwal SS, Berk M, Bjedov S, Bobes J, Bobes-Bascaran T, Bourgin-Duchesnay J, Bredicean CA, Bukelskis L, Burkadze A, Abud IIC, Castilla-Puentes R, Cetkovich M, Colon-Rivera H, Corral R, Cortez-Vergara C, Crepin P, De Berardis D, Zamora Delgado S, De Lucena D, De Sousa A, Stefano RD, Dodd S, Elek LP, Elissa A, Erdelyi-Hamza B, Erzin G, Etchevers MJ, Falkai P, Farcas A, Fedotov I, Filatova V, Fountoulakis NK, Frankova I, Franza F, Frias P, Galako T, Garay CJ, Garcia-Álvarez L, García-Portilla MP, Gonda X, Gondek TM, González DM, Gould H, Grandinetti P, Grau A, Groudeva V, Hagin M, Harada T, Hasan MT, Hashim NA, Hilbig J, Hossain S, Iakimova R, Ibrahim M, Iftene F, Ignatenko Y, Irarrazaval M, Ismail Z, Ismayilova J, Jacobs A, Jakovljevic M, Jakšic N, Javed A, Kafali HY, Karia S, Kazakova O, Khalifa D, Khaustova O, Koh S, Kopishinskaia S, Kosenko K, Koupidis SA, Kovacs I, Kulig B, Lalljee A, Liewig J, Majid A, Malashonkova E, Malik K, Malik NI, Mammadzada G, Mandalia B, Marazziti D, Marcinko D, Martinez S, Matiekus E, Mejia G, Memon RS, Martínez XEM, Mickeviciute D, Milev R, Mohammed M, Molina-López A, Morozov P, Muhammad NS, Mustac F, Naor MS, Nassieb A, Navickas A, Okasha T, Pandova M, Panfil AL, Panteleeva L, Papava I, Patsali ME, Pavlichenko A, Pejuskovic B, Pinto Da Costa M, Popkov M, Popovic D, Raduan NJN, Ramírez FV, Rancans E, Razali S, Rebok F, Rewekant A, Flores ENR, Rivera-Encinas MT, Saiz P, de Carmona MS, Martínez DS, Saw JA, Saygili G, Schneidereit P, Shah B, Shirasaka T, Silagadze K, Sitanggang S, Skugarevsky O, Spikina A, Mahalingappa SS, Stoyanova M, Szczegielniak A, Tamasan SC, Tavormina G, Tavormina MGM, Theodorakis PN, Tohen M, Tsapakis EM, Tukhvatullina D, Ullah I, Vaidya R, Vega-Dienstmaier JM, Vrublevska J, Vukovic O, Vysotska O, Widiasih N, Yashikhina A, Prezerakos PE, Smirnova D
Results of the COVID-19 mental health international for the general population (COMET-G) study. Eur Neuropsychopharmacol. 2022 01; 54:21-40.
Results of the COVID-19 mental health international for the general population (COMET-G) study.
Gonzalez R, Dwivedi A, Zeitzer J, Suppes T, Tohen M, Forero A, Alvarado A
Chronbiologically-based sub-groups in bipolar I disorder: A latent profile analysis. J Affect Disord. 2022 02 15; 299:691-697.
Chronbiologically-based sub-groups in bipolar I disorder: A latent profile analysis.
Kuperberg M, Köhler-Forsberg O, Shannon AP, George N, Greenebaum S, Bowden CL, Calabrese JR, Thase M, Shelton RC, McInnis M, Deckersbach T, Tohen M, Kocsis JH, Ketter TA, Friedman ES, Iosifescu DV, Ostacher MJ, Sylvia LG, McElroy SL, Nierenberg AA
Cardiometabolic risk markers during mood-stabilizing treatment: Correlation with drug-specific effects, depressive symptoms and treatment response. J Affect Disord. 2022 03 01; 300:41-49.
Cardiometabolic risk markers during mood-stabilizing treatment: Correlation with drug-specific effects, depressive symptoms and treatment response.
Lithium treatment of Bipolar disorder in adults: A systematic review of randomized trials and meta-analyses. Eur Neuropsychopharmacol. 2022 01; 54:100-115.
Lithium treatment of Bipolar disorder in adults: A systematic review of randomized trials and meta-analyses.
Wrobel AL, Köhler-Forsberg O, Sylvia LG, Russell SE, Dean OM, Cotton SM, Thase M, Calabrese JR, Deckersbach T, Tohen M, Bowden CL, McInnis MG, Kocsis JH, Friedman ES, Ketter TA, Shelton RC, Ostacher MJ, Iosifescu DV, Berk M, Turner A, Nierenberg AA
Childhood trauma and treatment outcomes during mood-stabilising treatment with lithium or quetiapine among outpatients with bipolar disorder. Acta Psychiatr Scand. 2022 06; 145(6):615-627.
Childhood trauma and treatment outcomes during mood-stabilising treatment with lithium or quetiapine among outpatients with bipolar disorder.
Köhler-Forsberg O, Sylvia LG, Thase M, Calabrese JR, Tohen M, Bowden CL, McInnis M, Iosifescu DV, Kocsis JH, Friedman ES, Ketter TA, McElroy SL, Shelton RC, Fung V, Ostacher MJ, Nierenberg AA
The Australian and New Zealand journal of psychiatry
Lithium plus antipsychotics or anticonvulsants for bipolar disorder: Comparing clinical response and metabolic changes. Aust N Z J Psychiatry. 2023 01; 57(1):93-103.
Lithium plus antipsychotics or anticonvulsants for bipolar disorder: Comparing clinical response and metabolic changes.
Fountoulakis KN, Karakatsoulis GN, Abraham S, Adorjan K, Ahmed HU, Alarcón RD, Arai K, Auwal SS, Berk M, Bjedov S, Bobes J, Bobes-Bascaran T, Bourgin-Duchesnay J, Bredicean CA, Bukelskis L, Burkadze A, Abud IIC, Castilla-Puentes R, Cetkovich M, Colon-Rivera H, Corral R, Cortez-Vergara C, Crepin P, De Berardis D, Delgado SZ, De Lucena D, De Sousa A, Stefano RD, Dodd S, Elek LP, Elissa A, Erdelyi-Hamza B, Erzin G, Etchevers MJ, Falkai P, Farcas A, Fedotov I, Filatova V, Fountoulakis NK, Frankova I, Franza F, Frias P, Galako T, Garay CJ, Garcia-Álvarez L, García-Portilla MP, Gonda X, Gondek TM, González DM, Gould H, Grandinetti P, Grau A, Groudeva V, Hagin M, Harada T, Hasan TM, Hashim NA, Hilbig J, Hossain S, Iakimova R, Ibrahim M, Iftene F, Ignatenko Y, Irarrazaval M, Ismail Z, Ismayilova J, Jacobs A, Jakovljevic M, Jakšic N, Javed A, Kafali HY, Karia S, Kazakova O, Khalifa D, Khaustova O, Koh S, Kopishinskaia S, Kosenko K, Koupidis SA, Kovacs I, Kulig B, Lalljee A, Liewig J, Majid A, Malashonkova E, Malik K, Malik NI, Mammadzada G, Mandalia B, Marazziti D, Marcinko D, Martinez S, Matiekus E, Mejia G, Memon RS, Martínez XEM, Mickeviciute D, Milev R, Mohammed M, Molina-López A, Morozov P, Muhammad NS, Mustac F, Naor MS, Nassieb A, Navickas A, Okasha T, Pandova M, Panfil AL, Panteleeva L, Papava I, Patsali ME, Pavlichenko A, Pejuskovic B, Da Costa MP, Popkov M, Popovic D, Raduan NJN, Ramírez FV, Rancans E, Razali S, Rebok F, Rewekant A, Flores ENR, Rivera-Encinas MT, Saiz P, de Carmona MS, Martínez DS, Saw JA, Saygili G, Schneidereit P, Shah B, Shirasaka T, Silagadze K, Sitanggang S, Skugarevsky O, Spikina A, Mahalingappa SS, Stoyanova M, Szczegielniak A, Tamasan SC, Tavormina G, Tavormina MGM, Theodorakis PN, Tohen M, Tsapakis EM, Tukhvatullina D, Ullah I, Vaidya R, Vega-Dienstmaier JM, Vrublevska J, Vukovic O, Vysotska O, Widiasih N, Yashikhina A, Prezerakos PE, Smirnova D
The effect of different degrees of lockdown and self-identified gender on anxiety, depression and suicidality during the COVID-19 pandemic: Data from the international COMET-G study. Psychiatry Res. 2022 09; 315:114702.
The effect of different degrees of lockdown and self-identified gender on anxiety, depression and suicidality during the COVID-19 pandemic: Data from the international COMET-G study.
The field of bipolar disorders has lost a pioneer - Charlie Bowden. J Affect Disord. 2022 12 15; 319:608-609.
The field of bipolar disorders has lost a pioneer - Charlie Bowden.
Ratheesh A, Hett D, Ramain J, Wong E, Berk L, Conus P, Fristad MA, Goldstein T, Hillegers M, Jauhar S, Kessing LV, Miklowitz DJ, Murray G, Scott J, Tohen M, Yatham LN, Young AH, Berk M, Marwaha S
A systematic review of interventions in the early course of bipolar disorder I or II: a report of the International Society for Bipolar Disorders Taskforce on early intervention. Int J Bipolar Disord. 2023 Jan 03; 11(1):1.
A systematic review of interventions in the early course of bipolar disorder I or II: a report of the International Society for Bipolar Disorders Taskforce on early intervention.
Suppes T, Durgam S, Kozauer SG, Chen R, Lakkis HD, Davis RE, Satlin A, Vanover KE, Mates S, McIntyre RS, Tohen M
Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-controlled clinical trial. Bipolar Disord. 2023 09; 25(6):478-488.
Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-controlled clinical trial.
N Fountoulakis K, N Karakatsoulis G, Abraham S, Adorjan K, Ahmed HU, Alarcón RD, Arai K, Auwal SS, Bobes J, Bobes-Bascaran T, Bourgin-Duchesnay J, Bredicean CA, Bukelskis L, Burkadze A, Cabrera Abud II, Castilla-Puentes R, Cetkovich M, Colon-Rivera H, Corral R, Cortez-Vergara C, Crepin P, de Berardis D, Zamora Delgado S, de Lucena D, de Sousa A, di Stefano R, Dodd S, Elek LP, Elissa A, Erdelyi-Hamza B, Erzin G, Etchevers MJ, Falkai P, Farcas A, Fedotov I, Filatova V, Fountoulakis NK, Frankova I, Franza F, Frias P, Galako T, Garay CJ, Garcia-Álvarez L, García-Portilla P, Gonda X, Gondek TM, Morera González D, Gould H, Grandinetti P, Grau A, Groudeva V, Hagin M, Harada T, Hasan TM, Azreen Hashim N, Hilbig J, Hossain S, Iakimova R, Ibrahim M, Iftene F, Ignatenko Y, Irarrazaval M, Ismail Z, Ismayilova J, Jacobs A, Jakovljevic M, Jakšic N, Javed A, Yilmaz Kafali H, Karia S, Kazakova O, Khalifa D, Khaustova O, Koh S, Kopishinskaia S, Kosenko K, Koupidis SA, Kovacs I, Kulig B, Lalljee A, Liewig J, Majid A, Malashonkova E, Malik K, Iqbal Malik N, Mammadzada G, Mandalia B, Marazziti D, Marcinko D, Martinez S, Matiekus E, Mejia G, Memon RS, Meza Martínez XE, Mickeviciute D, Milev R, Mohammed M, Molina-López A, Morozov P, Muhammad NS, Mustac F, Naor MS, Nassieb A, Navickas A, Okasha T, Pandova M, Panfil AL, Panteleeva L, Papava I, Patsali ME, Pavlichenko A, Pejuskovic B, Pinto da Costa M, Popkov M, Popovic D, Raduan NJN, Vargas Ramírez F, Rancans E, Razali S, Rebok F, Rewekant A, Reyes Flores EN, Rivera-Encinas MT, Saiz PA, Sánchez de Carmona M, Saucedo Martínez D, Saw JA, Saygili G, Schneidereit P, Shah B, Shirasaka T, Silagadze K, Sitanggang S, Skugarevsky O, Spikina A, Mahalingappa SS, Stoyanova M, Szczegielniak A, Tamasan SC, Tavormina G, Tavormina MGM, Theodorakis PN, Tohen M, Tsapakis EM, Tukhvatullina D, Ullah I, Vaidya R, Vega-Dienstmaier JM, Vrublevska J, Vukovic O, Vysotska O, Widiasih N, Yashikhina A, Prezerakos PE, Berk M, Levaj S, Smirnova D
Social psychiatry and psychiatric epidemiology
Results of the COVID-19 mental health international for the health professionals (COMET-HP) study: depression, suicidal tendencies and conspiracism. Soc Psychiatry Psychiatr Epidemiol. 2023 Sep; 58(9):1387-1410.
Results of the COVID-19 mental health international for the health professionals (COMET-HP) study: depression, suicidal tendencies and conspiracism.
Salvatore P, Indic P, Khalsa HK, Tohen M, Baldessarini RJ, Maggini C
Circadian Activity Rhythms and Psychopathology in Major Depressive Episodes. Psychopathology. 2024; 57(1):1-9.
Circadian Activity Rhythms and Psychopathology in Major Depressive Episodes.
Fountoulakis KN, Ioannou M, Tohen M, Haarman BCM, Zarate CA
Antidepressant efficacy of cariprazine in bipolar disorder and the role of its pharmacodynamic properties: A hypothesis based on data. Eur Neuropsychopharmacol. 2023 07; 72:30-39.
Antidepressant efficacy of cariprazine in bipolar disorder and the role of its pharmacodynamic properties: A hypothesis based on data.
Barans S, Friedman B, Lardier DT, Saavedra JL, Bustillo JR, Halperin D, Lenroot RK, Tohen M, Winger S, Crisanti AS
Trauma exposure and disclosure in Hispanic youth at clinical high risk for psychosis: A retrospective review study. Early Interv Psychiatry. 2024 Jan; 18(1):58-62.
Trauma exposure and disclosure in Hispanic youth at clinical high risk for psychosis: A retrospective review study.
Saavedra JL, Crisanti A, Lardier DT, Tohen M, Lenroot R, Bustillo J, Halperin D, Friedman B, Loewy R, Murray-Krezan C, McIver S
The Cascade of Care for Early Psychosis Detection in a College Counseling Center. Psychiatr Serv. 2024 Feb 01; 75(2):161-166.
The Cascade of Care for Early Psychosis Detection in a College Counseling Center.
Fountoulakis KN, Karakatsoulis GN, Abraham S, Adorjan K, Ahmed HU, Alarcón RD, Arai K, Auwal SS, Berk M, Bjedov S, Bobes J, Bobes-Bascaran T, Bourgin-Duchesnay J, Bredicean CA, Bukelskis L, Burkadze A, Cabrera Abud II, Castilla-Puentes R, Cetkovich M, Colon-Rivera H, Corral R, Cortez-Vergara C, Crepin P, De Berardis D, Zamora Delgado S, Lucena D, Sousa A, Stefano RD, Dodd S, Priyanka Elek L, Elissa A, Erdelyi-Hamza B, Erzin G, Etchevers MJ, Falkai P, Farcas A, Fedotov I, Filatova V, Fountoulakis NK, Frankova I, Franza F, Frias P, Galako T, Garay CJ, Garcia-Álvarez L, García-Portilla MP, Gonda X, Gondek TM, Morera González D, Gould H, Grandinetti P, Grau A, Groudeva V, Hagin M, Harada T, Hasan TM, Azreen Hashim N, Hilbig J, Hossain S, Iakimova R, Ibrahim M, Iftene F, Ignatenko Y, Irarrazaval M, Ismail Z, Ismayilova J, Jakobs A, Jakovljevic M, Jakšic N, Javed A, Kafali HY, Karia S, Kazakova O, Khalifa D, Khaustova O, Koh S, Kopishinskaia S, Kosenko K, Koupidis SA, Kovacs I, Kulig B, Lalljee A, Liewig J, Majid A, Malashonkova E, Malik K, Malik NI, Mammadzada G, Mandalia B, Marazziti D, Marcinko D, Martinez S, Matiekus E, Mejia G, Memon RS, Meza Martínez XE, Mickeviciute D, Milev R, Mohammed M, Molina-López A, Morozov P, Muhammad NS, Mustac F, Naor MS, Nassieb A, Navickas A, Okasha T, Pandova M, Panfil AL, Panteleeva L, Papava I, Patsali ME, Pavlichenko A, Pejuskovic B, Pinto Da Costa M, Popkov M, Popovic D, Raduan NJN, Vargas Ramírez F, Rancans E, Razali S, Rebok F, Rewekant A, Ninoska Reyes Flores E, Rivera-Encinas MT, Saiz P, Sánchez de Carmona M, Saucedo Martínez D, Saw JA, Saygili G, Schneidereit P, Shah B, Shirasaka T, Silagadze K, Sitanggang S, Skugarevsky O, Spikina A, Mahalingappa SS, Stoyanova M, Szczegielniak A, Tamasan SC, Tavormina G, Tavormina MGM, Theodorakis PN, Tohen M, Tsapakis EM, Tukhvatullina D, Ullah I, Vaidya R, Vega-Dienstmaier JM, Vrublevska J, Vukovic O, Vysotska O, Widiasih N, Yashikhina A, Prezerakos PE, Smirnova D
Somatic multicomorbidity and disability in patients with psychiatric disorders in comparison to the general population: a quasi-epidemiological investigation in 54,826 subjects from 40 countries (COMET-G study). CNS Spectr. 2024 04; 29(2):126-149.
Somatic multicomorbidity and disability in patients with psychiatric disorders in comparison to the general population: a quasi-epidemiological investigation in 54,826 subjects from 40 countries (COMET-G study).
Pharmacodynamic properties of lumateperone and its efficacy in acute bipolar depression: a mechanistic hypothesis based on data. Eur Neuropsychopharmacol. 2024 Apr; 81:1-9.
Pharmacodynamic properties of lumateperone and its efficacy in acute bipolar depression: a mechanistic hypothesis based on data.
Fountoulakis KN, Vrublevska J, Abraham S, Adorjan K, Ahmed HU, Alarcón RD, Arai K, Auwal SS, Berk M, Bjedov S, Bobes J, Bobes-Bascaran T, Bourgin-Duchesnay J, Bredicean CA, Bukelskis L, Burkadze A, Abud IIC, Castilla-Puentes R, Cetkovich M, Colon-Rivera H, Corral R, Cortez-Vergara C, Crepin P, De Berardis D, Delgado SZ, De Lucena D, De Sousa A, Di Stefano R, Dodd S, Elek LP, Elissa A, Erdelyi-Hamza B, Erzin G, Etchevers MJ, Falkai P, Farcas A, Fedotov I, Filatova V, Fountoulakis NK, Frankova I, Franza F, Frias P, Galako T, Garay CJ, Garcia-Álvarez L, García-Portilla MP, Gonda X, Gondek TM, González DM, Gould H, Grandinetti P, Grau A, Groudeva V, Hagin M, Harada T, Hasan TM, Hashim NA, Hilbig J, Hossain S, Iakimova R, Ibrahim M, Iftene F, Ignatenko Y, Irarrazaval M, Ismail Z, Ismayilova J, Jacobs A, Jakovljevic M, Jakšic N, Javed A, Kafali HY, Karia S, Kazakova O, Khalifa D, Khaustova O, Koh S, Kosenko K, Koupidis SA, Lalljee A, Liewig J, Majid A, Malashonkova E, Malik K, Malik NI, Mammadzada G, Mandalia B, Marazziti D, Marcinko D, Martinez S, Matiekus E, Mejia G, Memon RS, Martínez XEM, Mickeviciute D, Milev R, Mohammed M, Molina-López A, Morozov P, Muhammad NS, Mustac F, Naor MS, Nassieb A, Navickas A, Okasha T, Pandova M, Panfil AL, Panteleeva L, Papava I, Patsali ME, Pavlichenko A, Pejuskovic B, Da Costa MP, Popkov M, Popovic D, Raduan NJN, Ramírez FV, Rancans E, Razali S, Rebok F, Rewekant A, Flores ENR, Rivera-Encinas MT, Saiz P, de Carmona MS, Martínez DS, Saw JA, Saygili G, Schneidereit P, Shah B, Shirasaka T, Silagadze K, Sitanggang S, Skugarevsky O, Spikina A, Mahalingappa SS, Stoyanova M, Szczegielniak A, Tamasan SC, Tavormina G, Tavormina MGM, Theodorakis PN, Tohen M, Tsapakis EM, Tukhvatullina D, Ullah I, Vaidya R, Vega-Dienstmaier JM, Vukovic O, Vysotska O, Widiasih N, Yashikhina A, Smirnova D
Non-binary gender, vulnerable populations and mental health during the COVID-19 pandemic: Data from the COVID-19 MEntal health inTernational for the general population (COMET-G) study. J Affect Disord. 2024 05 01; 352:536-551.
Non-binary gender, vulnerable populations and mental health during the COVID-19 pandemic: Data from the COVID-19 MEntal health inTernational for the general population (COMET-G) study.
Early improvement with cariprazine as a predictor of antidepressant, anxiolytic, and antimanic response in bipolar I mania and depression: A pooled post hoc analysis of randomized cariprazine trials. J Affect Disord. 2024 Oct 01; 362:194-200.
Early improvement with cariprazine as a predictor of antidepressant, anxiolytic, and antimanic response in bipolar I mania and depression: A pooled post hoc analysis of randomized cariprazine trials.
Gonzalez R, Tamminga C, Tohen M, Suppes T
Comparison of objective and subjective assessments of sleep time in subjects with bipolar disorder. J Affect Disord. 2013 Jul; 149(1-3):363-6.
Comparison of objective and subjective assessments of sleep time in subjects with bipolar disorder.
Salvatore P, Baldessarini RJ, Khalsa HM, Amore M, Di Vittorio C, Ferraro G, Maggini C, Tohen M
Predicting diagnostic change among patients diagnosed with first-episode DSM-IV-TR major depressive disorder with psychotic features. J Clin Psychiatry. 2013 Jul; 74(7):723-31; quiz 731.
Predicting diagnostic change among patients diagnosed with first-episode DSM-IV-TR major depressive disorder with psychotic features.
Katagiri H, Tohen M, McDonnell DP, Fujikoshi S, Case M, Kanba S, Takahashi M, Gomez JC
Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study. BMC Psychiatry. 2013 May 14; 13:138.
Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study.
Credibility of industry-funded clinical trials. Int J Neuropsychopharmacol. 2013 Sep; 16(8):1879-84.
Credibility of industry-funded clinical trials.
Tohen M, Katagiri H, Fujikoshi S, Kanba S
Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies. J Affect Disord. 2013 Jul; 149(1-3):196-201.
Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies.
Wrobel AL, Turner M, Dean OM, Berk M, Sylvia LG, Thase ME, Deckersbach T, Tohen M, McInnis MG, Kocsis JH, Shelton RC, Ostacher MJ, Iosifescu DV, McElroy SL, Turner A, Nierenberg AA
Understanding the relationship between childhood abuse and affective symptoms in bipolar disorder: New insights from a network analysis. Psychiatry Res. 2024 Dec; 342:116197.
Understanding the relationship between childhood abuse and affective symptoms in bipolar disorder: New insights from a network analysis.
Vieta E, Tohen M, McIntosh D, Kessing LV, Sajatovic M, McIntyre RS
Early use of long-acting injectable antipsychotics in bipolar disorder type I: An expert consensus. Bipolar Disord. 2025 Feb; 27(1):7-16.
Early use of long-acting injectable antipsychotics in bipolar disorder type I: An expert consensus.
Bell Lynum KS, Castro CF, Zhang Z, Patel M, Tohen M
Aripiprazole once-monthly for the treatment of adult patients with earlier-stage bipolar I disorder: a post hoc analysis of data from a double-blind, placebo-controlled, 52-week randomized withdrawal trial. Int J Bipolar Disord. 2024 Oct 27; 12(1):37.
Aripiprazole once-monthly for the treatment of adult patients with earlier-stage bipolar I disorder: a post hoc analysis of data from a double-blind, placebo-controlled, 52-week randomized withdrawal trial.
McIntyre RS, Tohen M, Berk M, Zhao J, Weiller E
DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data. J Affect Disord. 2013 Sep 05; 150(2):378-83.
DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data.
Barans S, Saavedra JL, Lardier DT, Tohen M, Lenroot R, Bustillo J, Halperin D, Friedman B, Loewy R, Murray-Krezan C, McIver S, Crisanti AS
Characteristics Associated with Engagement in the Early Detection Cascade of Care for Psychosis at a College Counseling Center. Community Ment Health J. 2025 Jul; 61(5):913-922.
Characteristics Associated with Engagement in the Early Detection Cascade of Care for Psychosis at a College Counseling Center.
Sylvia LG, Friedman ES, Kocsis JH, Bernstein EE, Brody BD, Kinrys G, Kemp DE, Shelton RC, McElroy SL, Bobo WV, Kamali M, McInnis MG, Tohen M, Bowden CL, Ketter TA, Deckersbach T, Calabrese JR, Thase ME, Reilly-Harrington NA, Singh V, Rabideau DJ, Nierenberg AA
Association of exercise with quality of life and mood symptoms in a comparative effectiveness study of bipolar disorder. J Affect Disord. 2013 Nov; 151(2):722-727.
Association of exercise with quality of life and mood symptoms in a comparative effectiveness study of bipolar disorder.
Kemp DE, Correll CU, Tohen M, Delbello MP, Ganocy SJ, Findling RL, Chang K
Journal of child and adolescent psychopharmacology
Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia. J Child Adolesc Psychopharmacol. 2013 Oct; 23(8):522-30.
Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia.
Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, Post RM, Berk M, Goodwin GM, Sachs GS, Tondo L, Findling RL, Youngstrom EA, Tohen M, Undurraga J, González-Pinto A, Goldberg JF, Yildiz A, Altshuler LL, Calabrese JR, Mitchell PB, Thase ME, Koukopoulos A, Colom F, Frye MA, Malhi GS, Fountoulakis KN, Vázquez G, Perlis RH, Ketter TA, Cassidy F, Akiskal H, Azorin JM, Valentí M, Mazzei DH, Lafer B, Kato T, Mazzarini L, Martínez-Aran A, Parker G, Souery D, Ozerdem A, McElroy SL, Girardi P, Bauer M, Yatham LN, Zarate CA, Nierenberg AA, Birmaher B, Kanba S, El-Mallakh RS, Serretti A, Rihmer Z, Young AH, Kotzalidis GD, MacQueen GM, Bowden CL, Ghaemi SN, Lopez-Jaramillo C, Rybakowski J, Ha K, Perugi G, Kasper S, Amsterdam JD, Hirschfeld RM, Kapczinski F, Vieta E
The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013 Nov; 170(11):1249-62.
The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders.
Kumar P, Moomtaheen F, Malec SA, Yang JJ, Bologa CG, Schneider KA, Zhu Y, Tohen M, Villarreal G, Perkins DJ, Fielstein EM, Davis SE, Matheny ME, Lambert CG
IEEE journal of biomedical and health informatics
Detecting Opioid Use Disorder in Health Claims Data With Positive Unlabeled Learning. IEEE J Biomed Health Inform. 2025 02; 29(2):750-757.
Detecting Opioid Use Disorder in Health Claims Data With Positive Unlabeled Learning.
Salvatore P, Khalsa HK, Baldessarini RJ, Tohen M
The Journal of nervous and mental disease
Suicide Attempts in First Episodes of Major Psychiatric Disorders With Psychotic Features. J Nerv Ment Dis. 2025 Apr-May 01; 213(4):108-116.
Suicide Attempts in First Episodes of Major Psychiatric Disorders With Psychotic Features.
Fountoulakis KN, Karakatsoulis G, Abraham S, Adorjan K, Ahmed HU, Alarcón RD, Arai K, Auwal SS, Berk M, Levaj S, Bobes J, Bobes-Bascaran T, Bourgin-Duchesnay J, Bredicean CA, Bukelskis L, Burkadze A, Abud IIC, Castilla-Puentes R, Cetkovich M, Colon-Rivera H, Corral R, Cortez-Vergara C, Crepin P, De Berardis D, Delgado SZ, De Lucena D, De Sousa A, Stefano RD, Dodd S, Elek LP, Elissa A, Erdelyi-Hamza B, Erzin G, Etchevers MJ, Falkai P, Farcas A, Fedotov I, Filatova V, Fountoulakis NK, Frankova I, Franza F, Frias P, Galako T, Garay CJ, Garcia-Álvarez L, García-Portilla MP, Gonda X, Gondek TM, González DM, Gould H, Grandinetti P, Grau A, Groudeva V, Hagin M, Harada T, Hasan TM, Razali S, Hilbig J, Hossain S, Iakimova R, Ibrahim M, Iftene F, Ignatenko Y, Irarrazaval M, Ismail Z, Ismayilova J, Jakobs A, Jakovljevic M, Jakšic N, Javed A, Kafali HY, Karia S, Kazakova O, Khalifa D, Khaustova O, Koh S, Kopishinskaia S, Kosenko K, Vadon NB, Lalljee A, Liewig J, Majid A, Malashonkova E, Malik K, Malik NI, Mammadzada G, Mandalia B, Marazziti D, Marcinko D, Martinez S, Matiekus E, Mejia G, Memon RS, Martínez XEM, Mickeviciute D, Milev R, Mohammed M, Molina-López A, Morozov P, Muhammad NS, Mustac F, Naor MS, Nassieb A, Navickas A, Okasha T, Pandova M, Panfil AL, Panteleeva L, Papava I, Pavlichenko A, Pejuskovic B, da Costa MP, Popkov M, Popovic D, Raduan NJN, Ramírez FV, Rancans E, Hashim NA, Rebok F, Rewekant A, Flores ENR, Rivera-Encinas MT, Saiz P, de Carmona MS, Martínez DS, Saw JA, Saygili G, Schneidereit P, Shah B, Shirasaka T, Silagadze K, Sitanggang S, Skugarevsky O, Spikina A, Mahalingappa SS, Stoyanova M, Szczegielniak A, Tamasan SC, Tavormina G, Tavormina MGM, Tohen M, Tsapakis EM, Tukhvatullina D, Ullah I, Vaidya R, Vega-Dienstmaier JM, Vrublevska J, Vukovic O, Vysotska O, Widiasih N, Yashikhina A, Smirnova D
Treatment and long-term outcome of mental disorders: The grim picture from a quasi-epidemiological investigation in 54,826 subjects from 40 countries. Psychiatry Res. 2025 Jun; 348:116459.
Treatment and long-term outcome of mental disorders: The grim picture from a quasi-epidemiological investigation in 54,826 subjects from 40 countries.
Nierenberg AA, Sylvia LG, Leon AC, Reilly-Harrington NA, Shesler LW, McElroy SL, Friedman ES, Thase ME, Shelton RC, Bowden CL, Tohen M, Singh V, Deckersbach T, Ketter TA, Kocsis JH, McInnis MG, Schoenfeld D, Bobo WV, Calabrese JR
Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder (Bipolar CHOICE): a pragmatic trial of complex treatment for a complex disorder. Clin Trials. 2014 Feb; 11(1):114-27.
Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder (Bipolar CHOICE): a pragmatic trial of complex treatment for a complex disorder.
Salvatore P, Baldessarini RJ, Khalsa HM, Vázquez G, Perez J, Faedda GL, Amore M, Maggini C, Tohen M
Antecedents of manic versus other first psychotic episodes in 263 bipolar I disorder patients. Acta Psychiatr Scand. 2014 Apr; 129(4):275-85.
Antecedents of manic versus other first psychotic episodes in 263 bipolar I disorder patients.
Bobo WV, Reilly-Harrington NA, Ketter TA, Brody BD, Kinrys G, Kemp DE, Shelton RC, McElroy SL, Sylvia LG, Kocsis JH, McInnis MG, Friedman ES, Singh V, Tohen M, Bowden CL, Deckersbach T, Calabrese JR, Thase ME, Nierenberg AA, Rabideau DJ, Schoenfeld DA, Faraone SV, Kamali M
Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: results from the Bipolar CHOICE trial. J Affect Disord. 2014 Jun; 161:30-5.
Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: results from the Bipolar CHOICE trial.
Gonzalez R, Tamminga CA, Tohen M, Suppes T
The relationship between affective state and the rhythmicity of activity in bipolar disorder. J Clin Psychiatry. 2014 Apr; 75(4):e317-22.
The relationship between affective state and the rhythmicity of activity in bipolar disorder.
Tohen M, Kanba S, McIntyre RS, Fujikoshi S, Katagiri H
Efficacy of olanzapine monotherapy in the treatment of bipolar depression with mixed features. J Affect Disord. 2014 Aug; 164:57-62.
Efficacy of olanzapine monotherapy in the treatment of bipolar depression with mixed features.
Salvatore P, Bhuvaneswar C, Tohen M, Khalsa HM, Maggini C, Baldessarini RJ
Capgras' syndrome in first-episode psychotic disorders. Psychopathology. 2014; 47(4):261-9.
Capgras' syndrome in first-episode psychotic disorders.
Perlis RH, Verhaak PF, Goldberg J, Cusin C, Ostacher M, Malhi GS, Zarate CA, Shelton RC, Iosifescu DV, Tohen M, Jha MK, Sajatovic M, Berk M
Clinical decision support for pharmacologic management of treatment-resistant depression with augmented large language models. J Mood Anxiety Disord. 2025 Dec; 12:100142.
Clinical decision support for pharmacologic management of treatment-resistant depression with augmented large language models.
Do patients benefit from collaborations between industry and academia in psychopharmacological research? Eur Neuropsychopharmacol. 2025 Oct; 99:41-42.
Do patients benefit from collaborations between industry and academia in psychopharmacological research?
Tohen M, Yildirim M, Loomer S, Micheelsen A, Harrsen K, Beckham C, Nag S, Bates D, Guillaume X, Such P
Views on an antipsychotic regimen administered once every 2 months: a qualitative interview study of people living with bipolar I disorder, caregivers, and prescribers in the USA and Canada. Int J Bipolar Disord. 2026 Feb 18; 14(1).
Views on an antipsychotic regimen administered once every 2 months: a qualitative interview study of people living with bipolar I disorder, caregivers, and prescribers in the USA and Canada.
Goldberg JF, McIntyre RS, Swartz HA, Freeman MP, Mago R, Citrome L, Rosenblat JD, Thase ME, Tohen M, Vieta E, Malhi GS, Sajatovic M, Shelton RC, Macaluso M, Berk M, Perlis RH, Ostacher MJ, Khan A, Iosifescu DV, Sanacora G, Rubio JM, Kane JM, Goodman DW, Nierenberg AA, Correll CU, Kupka R, Kasper S, Furukawa TA, Davis L, Aaronson ST, Gitlin MJ, Jha MK, Cohen LJ, Papakostas GI, Mitchell PB, Gorwood P, Gupta S, Frye MA, Young AH, Zohar J, Steingard S, Zarate CA, Clayton AH
Recommendations for the Deprescribing of Psychotropic Medications: A Consensus Statement From the American Society of Clinical Psychopharmacology Task Force. JAMA Netw Open. 2026 Feb 02; 9(2):e260043.
Recommendations for the Deprescribing of Psychotropic Medications: A Consensus Statement From the American Society of Clinical Psychopharmacology Task Force.
Wrobel AL, Dean OM, Lotfaliany M, Berk M, Sylvia LG, Thase ME, Deckersbach T, Tohen M, McInnis MG, Kocsis JH, Shelton RC, McElroy SL, Turner A, Nierenberg AA
Potential Impact of Childhood Abuse on Quality of Life During Mood-Stabilising Treatment in Individuals Living With Bipolar Disorder. Bipolar Disord. 2026 Mar; 28(2):e70079.
Potential Impact of Childhood Abuse on Quality of Life During Mood-Stabilising Treatment in Individuals Living With Bipolar Disorder.
Tohen M, Durgam S, Kozauer SG, Chen C, Davis RE, Mates S
Long-term safety and tolerability of lumateperone 42?mg in patients with bipolar disorder: results from a 6-month open-label extension study. Int Clin Psychopharmacol. 2026 Mar 01; 41(2):130-137.
Long-term safety and tolerability of lumateperone 42?mg in patients with bipolar disorder: results from a 6-month open-label extension study.
Goldberg JF, Swartz HA, Mago R, McIntyre RS, Malhi GS, Rosenblat JD, Freeman MP, Vieta E, Thase ME, Tohen M, Citrome L
What Is Meant by the Term "Deprescribing," and Does It Belong in Our Lexicon? J Clin Psychiatry. 2025 Jun 02; 86(4).
What Is Meant by the Term "Deprescribing," and Does It Belong in Our Lexicon?
Vieta E, McIntyre RS, Suppes T, Van Rheenen TE, Singh B, Miskowiak KW, Young AH, Yatham LN, Ha K, Berk M, Swartz HA, Henry C, Stefanovic MP, Diaz GA, Ozerdem A, Cubala WJ, Hidalgo-Mazzei D, Tohen M, Pacchiarotti I, Nunes PV, Lopez-Jaramillo C, Gonzalez-Pinto A, Brambilla P, Post R, Soares JC, Bauer M, Andreazza AC, Fradera XJ, Cosials-Lopez M, Fico G
Defining Treatment-Resistant Bipolar Depression: Recommendations From the ISBD Task Force. Bipolar Disord. 2025 Sep; 27(6):411-423.
Defining Treatment-Resistant Bipolar Depression: Recommendations From the ISBD Task Force.
Turner A, Kuperberg M, McGovern H, Wrobel A, Dean OM, Berk M, Sylvia L, McElroy SL, Tohen M, Shelton RC, Iosifescu DV, Thase ME, Kocsis JH, Ostacher MJ, Deckersbach T, McInnis MG, Köhler-Forsberg O, Nierenberg AA
Adverse childhood experiences and cardiometabolic risk factors in people with bipolar disorder. J Affect Disord. 2026 Jan 15; 393(Pt A):120270.
Adverse childhood experiences and cardiometabolic risk factors in people with bipolar disorder.
Vega-Ramos S, Alvarez-Lesmes S, Arora-Guevara K, García-Bohórquez K, Tohen M, Lencz T, Malhotra AK, Gallego JA
medRxiv : the preprint server for health sciences
Parental Socio-economic Class and Obesity in Hispanic and non-Hispanic Individuals with First Episode Psychosis. medRxiv. 2025 Sep 23.
Parental Socio-economic Class and Obesity in Hispanic and non-Hispanic Individuals with First Episode Psychosis.
Safety and efficacy of olanzapine in the long-term treatment of Japanese patients with bipolar I disorder, depression: an integrated analysis. Psychiatry Clin Neurosci. 2014 Jul; 68(7):498-505.
Safety and efficacy of olanzapine in the long-term treatment of Japanese patients with bipolar I disorder, depression: an integrated analysis.
Tohen M, McIntyre RS, Kanba S, Fujikoshi S, Katagiri H
Efficacy of olanzapine in the treatment of bipolar mania with mixed features defined by DSM-5. J Affect Disord. 2014 Oct; 168:136-41.
Efficacy of olanzapine in the treatment of bipolar mania with mixed features defined by DSM-5.
Brunner E, Tohen M, Osuntokun O, Landry J, Thase ME
Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder. Neuropsychopharmacology. 2014 Oct; 39(11):2549-59.
Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder.
Calabrese JR, Fava M, Garibaldi G, Grunze H, Krystal AD, Laughren T, Macfadden W, Marin R, Nierenberg AA, Tohen M
Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders. J Affect Disord. 2014 Oct; 168:439-51.
Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders.
Kapczinski F, Magalhães PV, Balanzá-Martinez V, Dias VV, Frangou S, Gama CS, Gonzalez-Pinto A, Grande I, Ha K, Kauer-Sant'Anna M, Kunz M, Kupka R, Leboyer M, Lopez-Jaramillo C, Post RM, Rybakowski JK, Scott J, Strejilevitch S, Tohen M, Vazquez G, Yatham L, Vieta E, Berk M
Staging systems in bipolar disorder: an International Society for Bipolar Disorders Task Force Report. Acta Psychiatr Scand. 2014 Nov; 130(5):354-63.
Staging systems in bipolar disorder: an International Society for Bipolar Disorders Task Force Report.
Psychiatric collaborations in the Hispanic world. Rev Psiquiatr Salud Ment. 2014 Oct-Dec; 7(4):155-6.
Psychiatric collaborations in the Hispanic world.
Use of electroconvulsive therapy in bipolar depression. Am J Psychiatry. 2015 Jan; 172(1):3-5.
Use of electroconvulsive therapy in bipolar depression.
Complexity of illness and adjunctive benzodiazepine use in outpatients with bipolar I or II disorder: results from the Bipolar CHOICE study. J Clin Psychopharmacol. 2015 Feb; 35(1):68-74.
Complexity of illness and adjunctive benzodiazepine use in outpatients with bipolar I or II disorder: results from the Bipolar CHOICE study.
Sylvia LG, Shelton RC, Kemp DE, Bernstein EE, Friedman ES, Brody BD, McElroy SL, Singh V, Tohen M, Bowden CL, Ketter TA, Deckersbach T, Thase ME, Reilly-Harrington NA, Nierenberg AA, Rabideau DJ, Kinrys G, Kocsis JH, Bobo WV, Kamali M, McInnis MG, Calabrese JR
Medical burden in bipolar disorder: findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar CHOICE). Bipolar Disord. 2015 Mar; 17(2):212-23.
Medical burden in bipolar disorder: findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar CHOICE).
Sylvia LG, Thase ME, Reilly-Harrington NA, Salcedo S, Brody B, Kinrys G, Kemp D, Shelton RC, McElroy SL, Kocsis JH, Bobo WV, Kamali M, McInnis M, Friedman E, Tohen M, Bowden CL, Ketter TA, Singh V, Calabrese J, Nierenberg AA, Rabideau DJ, Elson CM, Deckersbach T
Psychotherapy use in bipolar disorder: Association with functioning and illness severity. Aust N Z J Psychiatry. 2015 May; 49(5):453-61.
Psychotherapy use in bipolar disorder: Association with functioning and illness severity.
Pharmacologic treatments for borderline personality disorder. Am J Psychiatry. 2014 Nov 01; 171(11):1139-41.
Pharmacologic treatments for borderline personality disorder.
Cariprazine in bipolar disorders. J Clin Psychiatry. 2015 Mar; 76(3):e368-70.
Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. Am J Psychiatry. 2015 Oct; 172(10):950-66.
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Zhang JP, Robinson DG, Gallego JA, John M, Yu J, Addington J, Tohen M, Kane JM, Malhotra AK, Lencz T
Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis. Schizophr Bull. 2015 Nov; 41(6):1248-55.
Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis.
Robinson DG, Gallego JA, John M, Petrides G, Hassoun Y, Zhang JP, Lopez L, Braga RJ, Sevy SM, Addington J, Kellner CH, Tohen M, Naraine M, Bennett N, Greenberg J, Lencz T, Correll CU, Kane JM, Malhotra AK
A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. Schizophr Bull. 2015 Nov; 41(6):1227-36.
A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes.
Trampush JW, Lencz T, DeRosse P, John M, Gallego JA, Petrides G, Hassoun Y, Zhang JP, Addington J, Kellner CH, Tohen M, Burdick KE, Goldberg TE, Kane JM, Robinson DG, Malhotra AK
Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders. Schizophr Bull. 2015 Nov; 41(6):1237-47.
Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders.
Stentebjerg-Olesen M, Ganocy SJ, Findling RL, Chang K, DelBello MP, Kane JM, Tohen M, Jeppesen P, Correll CU
Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial. Eur Child Adolesc Psychiatry. 2015 Dec; 24(12):1485-96.
Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial.
Psychotropic agents and the prediction of weight gain. J Clin Psychiatry. 2015 Nov; 76(11):e1474-5.
Psychotropic agents and the prediction of weight gain.
Multi-state outcome analysis of treatments (MOAT): application of a new approach to evaluate outcomes in longitudinal studies of bipolar disorder. Mol Psychiatry. 2016 Feb; 21(2):237-42.
Multi-state outcome analysis of treatments (MOAT): application of a new approach to evaluate outcomes in longitudinal studies of bipolar disorder.
Tondo L, Vázquez GH, Baethge C, Baronessa C, Bolzani L, Koukopoulos A, Mazzarini L, Murru A, Pacchiarotti I, Pinna M, Salvatore P, Sani G, Selle V, Spalletta G, Girardi P, Tohen M, Vieta E, Baldessarini RJ
Comparison of psychotic bipolar disorder, schizoaffective disorder, and schizophrenia: an international, multisite study. Acta Psychiatr Scand. 2016 Jan; 133(1):34-43.
Comparison of psychotic bipolar disorder, schizoaffective disorder, and schizophrenia: an international, multisite study.
Michalak EE, Jones S, Lobban F, Algorta GP, Barnes SJ, Berk L, Berk M, Hole R, Lapsley S, Maxwell V, Milev R, McManamy J, Murray G, Tohen M, Tse S, Sanchez de Carmona M, Johnson SL
Harnessing the potential of community-based participatory research approaches in bipolar disorder. Int J Bipolar Disord. 2016 Dec; 4(1):4.
Harnessing the potential of community-based participatory research approaches in bipolar disorder.
Deckersbach T, Nierenberg AA, McInnis MG, Salcedo S, Bernstein EE, Kemp DE, Shelton RC, McElroy SL, Sylvia LG, Kocsis JH, Bobo WV, Friedman ES, Singh V, Tohen M, Bowden CL, Ketter TA, Calabrese JR, Thase ME, Reilly-Harrington NA, Rabideau DJ, Kinrys G, Kamali M
Baseline disability and poor functioning in bipolar disorder predict worse outcomes: results from the Bipolar CHOICE study. J Clin Psychiatry. 2016 Jan; 77(1):100-8.
Baseline disability and poor functioning in bipolar disorder predict worse outcomes: results from the Bipolar CHOICE study.
Nierenberg AA, McElroy SL, Friedman ES, Ketter TA, Shelton RC, Deckersbach T, McInnis MG, Bowden CL, Tohen M, Kocsis JH, Calabrese JR, Kinrys G, Bobo WV, Singh V, Kamali M, Kemp D, Brody B, Reilly-Harrington NA, Sylvia LG, Shesler LW, Bernstein EE, Schoenfeld D, Rabideau DJ, Leon AC, Faraone S, Thase ME
Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): a pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder. J Clin Psychiatry. 2016 Jan; 77(1):90-9.
Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): a pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder.
Reilly-Harrington NA, Shelton RC, Kamali M, Rabideau DJ, Shesler LW, Trivedi MH, McElroy SL, Sylvia LG, Bowden CL, Ketter TA, Calabrese JR, Thase ME, Bobo WV, Deckersbach T, Tohen M, McInnis MG, Kocsis JH, Gold AK, Singh V, Finkelstein DM, Kinrys G, Nierenberg AA
A tool to predict suicidal ideation and behavior in bipolar disorder: The Concise Health Risk Tracking Self-Report. J Affect Disord. 2016 Mar 01; 192:212-8.
A tool to predict suicidal ideation and behavior in bipolar disorder: The Concise Health Risk Tracking Self-Report.
Analysis of bipolar maintenance treatment with lithium versus olanzapine utilizing Multi-state Outcome Analysis of Treatments (MOAT). Bipolar Disord. 2016 05; 18(3):282-7.
Analysis of bipolar maintenance treatment with lithium versus olanzapine utilizing Multi-state Outcome Analysis of Treatments (MOAT).
Lambert CG, Mazurie AJ, Lauve NR, Hurwitz NG, Young SS, Obenchain RL, Hengartner NW, Perkins DJ, Tohen M, Kerner B
Hypothyroidism risk compared among nine common bipolar disorder therapies in a large US cohort. Bipolar Disord. 2016 05; 18(3):247-60.
Hypothyroidism risk compared among nine common bipolar disorder therapies in a large US cohort.
In memoriam--Vivek Singh. J Affect Disord. 2016 Mar 15; 193:144.
Tohen M, Khalsa HM, Salvatore P, Zarate CA, Strakowski SM, Sanchez-Toledo JP, Baldessarini RJ
The McLean-Harvard First-Episode Project: Early Course in 114 Cases of First-Episode Nonaffective Psychoses. J Clin Psychiatry. 2016 06; 77(6):781-8.
The McLean-Harvard First-Episode Project: Early Course in 114 Cases of First-Episode Nonaffective Psychoses.
Ballard ED, Vande Voort JL, Luckenbaugh DA, Machado-Vieira R, Tohen M, Zarate CA
Acute risk factors for suicide attempts and death: prospective findings from the STEP-BD study. Bipolar Disord. 2016 06; 18(4):363-72.
Acute risk factors for suicide attempts and death: prospective findings from the STEP-BD study.
LONGITUDINAL STUDY OF FIRST EPISODE MANIA
PREDICTORS OF OUTCOME AFTER A FIRST-EPISODE OF PSYCHOSIS
Salvatore P, Baldessarini RJ, Khalsa HM, Indic P, Maggini C, Tohen M
Negative Affective Features in 516 Cases of First Psychotic Disorder Episodes: Relationship to Suicidal Risk. J Depress Anxiety. 2013 Jul 27; 2.
Negative Affective Features in 516 Cases of First Psychotic Disorder Episodes: Relationship to Suicidal Risk.
Reilly-Harrington NA, Sylvia LG, Rabideau DJ, Gold AK, Deckersbach T, Bowden CL, Bobo WV, Singh V, Calabrese JR, Shelton RC, Friedman ES, Thase ME, Kamali M, Tohen M, McInnis MG, McElroy SL, Ketter TA, Kocsis JH, Kinrys G, Nierenberg AA
Tracking medication changes to assess outcomes in comparative effectiveness research: A bipolar CHOICE study. J Affect Disord. 2016 Nov 15; 205:159-164.
Tracking medication changes to assess outcomes in comparative effectiveness research: A bipolar CHOICE study.
Malhi GS, Byrow Y, Cassidy F, Cipriani A, Demyttenaere K, Frye MA, Gitlin M, Kennedy SH, Ketter TA, Lam RW, McShane R, Mitchell AJ, Ostacher MJ, Rizvi SJ, Thase ME, Tohen M
Ketamine: stimulating antidepressant treatment? BJPsych Open. 2016 May; 2(3):e5-e9.
Ketamine: stimulating antidepressant treatment?
McElroy SL, Kemp DE, Friedman ES, Reilly-Harrington NA, Sylvia LG, Calabrese JR, Rabideau DJ, Ketter TA, Thase ME, Singh V, Tohen M, Bowden CL, Bernstein EE, Brody BD, Deckersbach T, Kocsis JH, Kinrys G, Bobo WV, Kamali M, McInnis MG, Leon AC, Faraone S, Nierenberg AA, Shelton RC
Obesity, but not metabolic syndrome, negatively affects outcome in bipolar disorder. Acta Psychiatr Scand. 2016 Feb; 133(2):144-153.
Obesity, but not metabolic syndrome, negatively affects outcome in bipolar disorder.
Machado-Vieira R, Luckenbaugh DA, Ballard ED, Henter ID, Tohen M, Suppes T, Zarate CA
Increased Activity or Energy as a Primary Criterion for the Diagnosis of Bipolar Mania in DSM-5: Findings From the STEP-BD Study. Am J Psychiatry. 2017 Jan 01; 174(1):70-76.
Increased Activity or Energy as a Primary Criterion for the Diagnosis of Bipolar Mania in DSM-5: Findings From the STEP-BD Study.
Cultural influences on suicide in Japan. Psychiatry Clin Neurosci. 2017 Jan; 71(1):2-5.
Cultural influences on suicide in Japan.
Köhler-Forsberg O, Sylvia L, Thase M, Calabrese JR, Deckersbach T, Tohen M, Bowden CL, McInnis M, Kocsis JH, Friedman ES, Ketter TA, McElroy S, Shelton RC, Nierenberg AA
Nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol do not affect 6-month mood-stabilizing treatment outcome among 482 patients with bipolar disorder. Depress Anxiety. 2017 03; 34(3):281-290.
Nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol do not affect 6-month mood-stabilizing treatment outcome among 482 patients with bipolar disorder.
Kirkpatrick B, Amador XF, Flaum M, Yale SA, Gorman JM, Carpenter WT, Tohen M, McGlashan T
The deficit syndrome in the DSM-IV Field Trial: I. Alcohol and other drug abuse. Schizophr Res. 1996 May; 20(1-2):69-77.
The deficit syndrome in the DSM-IV Field Trial: I. Alcohol and other drug abuse.
Kirkpatrick B, Amador XF, Yale SA, Bustillo JR, Buchanan RW, Tohen M
The deficit syndrome in the DSM-IV Field Trial. Part II. Depressive episodes and persecutory beliefs. Schizophr Res. 1996 May; 20(1-2):79-90.
The deficit syndrome in the DSM-IV Field Trial. Part II. Depressive episodes and persecutory beliefs.
Pillay SS, Stoll AL, Weiss MK, Tohen M, Zarate CA, Banov MD, Cole JO
Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists
EEG abnormalities before clozapine therapy predict a good clinical response to clozapine. Ann Clin Psychiatry. 1996 Mar; 8(1):1-5.
EEG abnormalities before clozapine therapy predict a good clinical response to clozapine.
Strakowski SM, Flaum M, Amador X, Bracha HS, Pandurangi AK, Robinson D, Tohen M
Racial differences in the diagnosis of psychosis. Schizophr Res. 1996 Aug 23; 21(2):117-24.
Racial differences in the diagnosis of psychosis.
Combined valproate or carbamazepine and electroconvulsive therapy. Ann Clin Psychiatry. 1997 Mar; 9(1):19-25.
Combined valproate or carbamazepine and electroconvulsive therapy.
Weiss RD, Greenfield SF, Najavits LM, Soto JA, Wyner D, Tohen M, Griffin ML
Medication compliance among patients with bipolar disorder and substance use disorder. J Clin Psychiatry. 1998 Apr; 59(4):172-4.
Medication compliance among patients with bipolar disorder and substance use disorder.
Antipsychotic drug treatment in first-episode mania: a 6-month longitudinal study. J Clin Psychiatry. 2000 Jan; 61(1):33-8.
Antipsychotic drug treatment in first-episode mania: a 6-month longitudinal study.
Tohen M, Baker RW, Altshuler LL, Zarate CA, Suppes T, Ketter TA, Milton DR, Risser R, Gilmore JA, Breier A, Tollefson GA
Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 2002 Jun; 159(6):1011-7.
Olanzapine versus divalproex in the treatment of acute mania.
Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry. 2004 Jan; 161(1):169-71.
Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients.
Cavazzoni PA, Berg PH, Kryzhanovskaya LA, Briggs SD, Roddy TE, Tohen M, Kane JM
Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. J Clin Psychiatry. 2006 Jan; 67(1):107-13.
Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials.
Applications of pharmacoepidemiology in psychiatry. Harv Rev Psychiatry. 1994 Jul-Aug; 2(2):117-8.
Applications of pharmacoepidemiology in psychiatry.
Tondo L, Baldessarini RJ, Hennen J, Floris G, Silvetti F, Tohen M
Lithium treatment and risk of suicidal behavior in bipolar disorder patients. J Clin Psychiatry. 1998 Aug; 59(8):405-14.
Lithium treatment and risk of suicidal behavior in bipolar disorder patients.
Kinney DK, Yurgelun-Todd DA, Tohen M, Tramer S
Pre- and perinatal complications and risk for bipolar disorder: a retrospective study. J Affect Disord. 1998 Sep; 50(2-3):117-24.
Pre- and perinatal complications and risk for bipolar disorder: a retrospective study.
Tohen M, Greenfield SF, Weiss RD, Zarate CA, Vagge LM
The effect of comorbid substance use disorders on the course of bipolar disorder: a review. Harv Rev Psychiatry. 1998 Sep-Oct; 6(3):133-41.
The effect of comorbid substance use disorders on the course of bipolar disorder: a review.
Sanger TM, Tohen M, Vieta E, Dunner DL, Bowden CL, Calabrese JR, Feldman PD, Jacobs TG, Breier A
Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. J Affect Disord. 2003 Jan; 73(1-2):155-61.
Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling.
Russo P, Smith MW, Dirani R, Namjoshi M, Tohen M
Pharmacotherapy patterns in the treatment of bipolar disorder. Bipolar Disord. 2002 Dec; 4(6):366-77.
Pharmacotherapy patterns in the treatment of bipolar disorder.
Berk M, Malhi GS, Mitchell PB, Cahill CM, Carman AC, Hadzi-Pavlovic D, Hawkins MT, Tohen M
Acta psychiatrica Scandinavica. Supplementum
Scale matters: the need for a Bipolar Depression Rating Scale (BDRS). Acta Psychiatr Scand Suppl. 2004; (422):39-45.
Scale matters: the need for a Bipolar Depression Rating Scale (BDRS).
Köhler O, Sylvia LG, Bowden CL, Calabrese JR, Thase M, Shelton RC, McInnis M, Tohen M, Kocsis JH, Ketter TA, Friedman ES, Deckersbach T, Ostacher MJ, Iosifescu DV, McElroy S, Nierenberg AA
White blood cell count correlates with mood symptom severity and specific mood symptoms in bipolar disorder. Aust N Z J Psychiatry. 2017 Apr; 51(4):355-365.
White blood cell count correlates with mood symptom severity and specific mood symptoms in bipolar disorder.
Psychiatric epidemiology. Harv Rev Psychiatry. 2000 Sep; 8(3):111-25.
Tohen M, Strakowski SM, Zarate C, Hennen J, Stoll AL, Suppes T, Faedda GL, Cohen BM, Gebre-Medhin P, Baldessarini RJ
The McLean-Harvard first-episode project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis. Biol Psychiatry. 2000 Sep 15; 48(6):467-76.
The McLean-Harvard first-episode project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis.
Gardner DM, Baldessarini RJ, Benzo J, Zarate CA, Tohen M
Switching between clozapine and risperidone treatment. Can J Psychiatry. 1997 May; 42(4):430-1.
Switching between clozapine and risperidone treatment.
Ketter TA, Houston JP, Adams DH, Risser RC, Meyers AL, Williamson DJ, Tohen M
Differential efficacy of olanzapine and lithium in preventing manic or mixed recurrence in patients with bipolar I disorder based on number of previous manic or mixed episodes. J Clin Psychiatry. 2006 Jan; 67(1):95-101.
Differential efficacy of olanzapine and lithium in preventing manic or mixed recurrence in patients with bipolar I disorder based on number of previous manic or mixed episodes.
Rosso IM, Killgore WD, Cintron CM, Gruber SA, Tohen M, Yurgelun-Todd DA
Reduced amygdala volumes in first-episode bipolar disorder and correlation with cerebral white matter. Biol Psychiatry. 2007 Mar 15; 61(6):743-9.
Reduced amygdala volumes in first-episode bipolar disorder and correlation with cerebral white matter.
Salvatore P, Tohen M, Khalsa HM, Baethge C, Tondo L, Baldessarini RJ
Longitudinal research on bipolar disorders. Epidemiol Psichiatr Soc. 2007 Apr-Jun; 16(2):109-17.
Longitudinal research on bipolar disorders.
Berk M, Ng F, Wang WV, Calabrese JR, Mitchell PB, Malhi GS, Tohen M
The empirical redefinition of the psychometric criteria for remission in bipolar disorder. J Affect Disord. 2008 Feb; 106(1-2):153-8.
The empirical redefinition of the psychometric criteria for remission in bipolar disorder.
Shi L, Namjoshi MA, Zhang F, Gandhi G, Edgell ET, Tohen M, Breier A, Haro JM
Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status. Int Clin Psychopharmacol. 2002 Sep; 17(5):227-37.
Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status.
Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, Keefe RS, Green AI, Gur RE, McEvoy J, Perkins D, Hamer RM, Gu H, Tohen M
Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry. 2005 Apr; 62(4):361-70.
Antipsychotic drug effects on brain morphology in first-episode psychosis.
Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, Koukopoulos A, Cassano GB, Grunze H, Licht RW, Dell'Osso L, Evans AR, Risser R, Baker RW, Crane H, Dossenbach MR, Bowden CL
Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry. 2005 Jul; 162(7):1281-90.
Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial.
Revicki DA, Tohen M, Gyulai L, Thompson C, Pike S, Davis-Vogel A, Zarate C
Telephone versus in-person clinical and health status assessment interviews in patients with bipolar disorder. Harv Rev Psychiatry. 1997 Jul-Aug; 5(2):75-81.
Telephone versus in-person clinical and health status assessment interviews in patients with bipolar disorder.
Shulman KI, Tohen M, Satlin A, Mallya G, Kalunian D
Mania compared with unipolar depression in old age. Am J Psychiatry. 1992 Mar; 149(3):341-5.
Mania compared with unipolar depression in old age.
Chengappa KN, Tohen M, Levine J, Jacobs T, Thase ME, Sanger TM, Kupfer DJ
Response to placebo among bipolar I disorder patients experiencing their first manic episode. Bipolar Disord. 2000 Dec; 2(4):332-5.
Response to placebo among bipolar I disorder patients experiencing their first manic episode.
Costa e Silva JA, Alvarez N, Mazzotti G, Gattaz WF, Ospina J, Larach V, Starkstein S, Oliva D, Cousins L, Tohen M, Taylor CC, Wang J, Tran PV
Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America. J Clin Psychopharmacol. 2001 Aug; 21(4):375-81.
Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America.
Caldieraro MA, Sylvia LG, Dufour S, Walsh S, Janos J, Rabideau DJ, Kamali M, McInnis MG, Bobo WV, Friedman ES, Gao K, Tohen M, Reilly-Harrington NA, Ketter TA, Calabrese JR, McElroy SL, Thase ME, Shelton RC, Bowden CL, Kocsis JH, Deckersbach T, Nierenberg AA
Clinical correlates of acute bipolar depressive episode with psychosis. J Affect Disord. 2017 08 01; 217:29-33.
Clinical correlates of acute bipolar depressive episode with psychosis.
Vieta E, Calabrese JR, Hennen J, Colom F, Martínez-Arán A, Sánchez-Moreno J, Yatham LN, Tohen M, Baldessarini RJ
Comparison of rapid-cycling and non-rapid-cycling bipolar I manic patients during treatment with olanzapine: analysis of pooled data. J Clin Psychiatry. 2004 Oct; 65(10):1420-8.
Comparison of rapid-cycling and non-rapid-cycling bipolar I manic patients during treatment with olanzapine: analysis of pooled data.
Khalsa HM, Salvatore P, Hennen J, Baethge C, Tohen M, Baldessarini RJ
Suicidal events and accidents in 216 first-episode bipolar I disorder patients: predictive factors. J Affect Disord. 2008 Feb; 106(1-2):179-84.
Suicidal events and accidents in 216 first-episode bipolar I disorder patients: predictive factors.
Chengappa KN, Baker RW, Shao L, Yatham LN, Tohen M, Gershon S, Kupfer DJ
Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania. Bipolar Disord. 2003 Feb; 5(1):1-5.
Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania.
Tohen M, Gold AK, Sylvia LG, Montana RE, McElroy SL, Thase ME, Rabideau DJ, Nierenberg AA, Reilly-Harrington NA, Friedman ES, Shelton RC, Bowden CL, Singh V, Deckersbach T, Ketter TA, Calabrese JR, Bobo WV, McInnis MG
Bipolar mixed features - Results from the comparative effectiveness for bipolar disorder (Bipolar CHOICE) study. J Affect Disord. 2017 08 01; 217:183-189.
Bipolar mixed features - Results from the comparative effectiveness for bipolar disorder (Bipolar CHOICE) study.
Lindenmayer JP, Brown E, Baker RW, Schuh LM, Shao L, Tohen M, Ahmed S, Stauffer VL
An excitement subscale of the Positive and Negative Syndrome Scale. Schizophr Res. 2004 Jun 01; 68(2-3):331-7.
An excitement subscale of the Positive and Negative Syndrome Scale.
Faedda GL, Baldessarini RJ, Tohen M, Strakowski SM, Waternaux C
Episode sequence in bipolar disorder and response to lithium treatment. Am J Psychiatry. 1991 Sep; 148(9):1237-9.
Episode sequence in bipolar disorder and response to lithium treatment.
Degenhardt EK, Tamayo JM, Jamal HH, Gatz J, Tohen M, Durell TM
Relationship between African-American or Caucasian origin and outcomes in the olanzapine treatment of acute mania: a pooled analysis of three adult studies conducted in the United States of America. Int Clin Psychopharmacol. 2011 May; 26(3):141-5.
Relationship between African-American or Caucasian origin and outcomes in the olanzapine treatment of acute mania: a pooled analysis of three adult studies conducted in the United States of America.
Variables as mediators or moderators in predicting relapse to any type of mood episode in a bipolar maintenance study. J Clin Psychiatry. 2012 Jul; 73(7):e913-7.
Variables as mediators or moderators in predicting relapse to any type of mood episode in a bipolar maintenance study.
Tohen M, Bowden CL, Calabrese JR, Lin D, Forrester TD, Sachs GS, Koukopoulos A, Yatham L, Grunze H
Influence of sub-syndromal symptoms after remission from manic or mixed episodes. Br J Psychiatry. 2006 Dec; 189:515-9.
Influence of sub-syndromal symptoms after remission from manic or mixed episodes.
Tohen M, Calabrese J, Vieta E, Bowden C, Gonzalez-Pinto A, Lin D, Xu W, Corya S
Effect of comorbid anxiety on treatment response in bipolar depression. J Affect Disord. 2007 Dec; 104(1-3):137-46.
Effect of comorbid anxiety on treatment response in bipolar depression.
Montoya A, Pérez Sánchez Toledo J, Gilaberte I, González-Pinto A, Haro JM, Vieta E, Tohen M
Patterns of drug treatment for manic episode in the clinical practice. Outcomes of the Spanish sample in the EMBLEM Study. Actas Esp Psiquiatr. 2007 Sep-Oct; 35(5):315-22.
Patterns of drug treatment for manic episode in the clinical practice. Outcomes of the Spanish sample in the EMBLEM Study.
Popli AP, Hegarty JD, Siegel AJ, Kando JC, Tohen M
Transfer of psychiatric inpatients to a general hospital due to adverse drug reactions. Psychosomatics. 1997 Jan-Feb; 38(1):35-7.
Transfer of psychiatric inpatients to a general hospital due to adverse drug reactions.
Tohen M, Stoll AL, Strakowski SM, Faedda GL, Mayer PV, Goodwin DC, Kolbrener ML, Madigan AM
The McLean First-Episode Psychosis Project: six-month recovery and recurrence outcome. Schizophr Bull. 1992; 18(2):273-82.
The McLean First-Episode Psychosis Project: six-month recovery and recurrence outcome.
Tohen M, Zhang F, Taylor CC, Burns P, Zarate C, Sanger T, Tollefson G
A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. J Affect Disord. 2001 Jun; 65(1):85-93.
A meta-analysis of the use of typical antipsychotic agents in bipolar disorder.
Gonzalez-Pinto A, Lalaguna B, Mosquera F, Pérez de Heredia JL, Gutierrez M, Ezcurra J, Gilaberte I, Tohen M
Use of olanzapine in dysphoric mania. J Affect Disord. 2001 Oct; 66(2-3):247-53.
McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, Hawkins KA, Hoffman R, Lindborg S, Tohen M, Breier A
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophr Res. 2003 May 01; 61(1):7-18.
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design.
Green AI, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick I, Clark WS
First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res. 2004 Feb 01; 66(2-3):125-35.
First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol.
Perkins D, Lieberman J, Gu H, Tohen M, McEvoy J, Green A, Zipursky R, Strakowski S, Sharma T, Kahn R, Gur R, Tollefson G
Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry. 2004 Jul; 185:18-24.
Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders.
Zarate CA, Narendran R, Tohen M, Greaney JJ, Berman A, Pike S, Madrid A
Clinical predictors of acute response with olanzapine in psychotic mood disorders. J Clin Psychiatry. 1998 Jan; 59(1):24-8.
Clinical predictors of acute response with olanzapine in psychotic mood disorders.
Kirkpatrick B, Ram R, Amador XF, Buchanan RW, McGlashan T, Tohen M, Bromet E
Summer birth and the deficit syndrome of schizophrenia. Am J Psychiatry. 1998 Sep; 155(9):1221-6.
Summer birth and the deficit syndrome of schizophrenia.
Management of acute mania. J Clin Psychiatry. 1999; 60 Suppl 5:31-4; discussion 35-6.
Zarate CA, Tohen M, Baraibar G, Zarate SB, Baldessarini RJ
Shifts in hospital diagnostic frequencies: bipolar disorder subtypes, 1981-1993. J Affect Disord. 1997 Mar; 43(1):79-84.
Shifts in hospital diagnostic frequencies: bipolar disorder subtypes, 1981-1993.
Salisbury DF, Shenton ME, Sherwood AR, Fischer IA, Yurgelun-Todd DA, Tohen M, McCarley RW
First-episode schizophrenic psychosis differs from first-episode affective psychosis and controls in P300 amplitude over left temporal lobe. Arch Gen Psychiatry. 1998 Feb; 55(2):173-80.
First-episode schizophrenic psychosis differs from first-episode affective psychosis and controls in P300 amplitude over left temporal lobe.
McCarley RW, Salisbury DF, Hirayasu Y, Yurgelun-Todd DA, Tohen M, Zarate C, Kikinis R, Jolesz FA, Shenton ME
Association between smaller left posterior superior temporal gyrus volume on magnetic resonance imaging and smaller left temporal P300 amplitude in first-episode schizophrenia. Arch Gen Psychiatry. 2002 Apr; 59(4):321-31.
Association between smaller left posterior superior temporal gyrus volume on magnetic resonance imaging and smaller left temporal P300 amplitude in first-episode schizophrenia.
DelBello MP, Carlson GA, Tohen M, Bromet EJ, Schwiers M, Strakowski SM
Rates and predictors of developing a manic or hypomanic episode 1 to 2 years following a first hospitalization for major depression with psychotic features. J Child Adolesc Psychopharmacol. 2003; 13(2):173-85.
Rates and predictors of developing a manic or hypomanic episode 1 to 2 years following a first hospitalization for major depression with psychotic features.
Hennen J, Perlis RH, Sachs G, Tohen M, Baldessarini RJ
Weight gain during treatment of bipolar I patients with olanzapine. J Clin Psychiatry. 2004 Dec; 65(12):1679-87.
Weight gain during treatment of bipolar I patients with olanzapine.
Medications for bipolar disorders: a review of their therapeutic and pharmacological differences. Part II: from sinapse to genes. Actas Esp Psiquiatr. 2004 Jan; 32 Suppl 1:18-37.
Medications for bipolar disorders: a review of their therapeutic and pharmacological differences. Part II: from sinapse to genes.
Collaboration to Reduce Tragedy and Improve Outcomes: Law Enforcement, Psychiatry, and People Living With Mental Illness. Am J Psychiatry. 2017 Jun 01; 174(6):513-517.
Collaboration to Reduce Tragedy and Improve Outcomes: Law Enforcement, Psychiatry, and People Living With Mental Illness.
Goetz I, Tohen M, Reed C, Lorenzo M, Vieta E
Functional impairment in patients with mania: baseline results of the EMBLEM study. Bipolar Disord. 2007 Feb-Mar; 9(1-2):45-52.
Functional impairment in patients with mania: baseline results of the EMBLEM study.
Niufan G, Tohen M, Qiuqing A, Fude Y, Pope E, McElroy H, Ming L, Gaohua W, Xinbao Z, Huichun L, Liang S
Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial. J Affect Disord. 2008 Jan; 105(1-3):101-8.
Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial.
Tamayo JM, Mazzotti G, Tohen M, Gattaz WF, Zapata R, Castillo JJ, Fahrer RD, González-Pinto AM, Vieta E, Azorin JM, Brown E, Brunner E, Rovner J, Bonett-Perrin E, Baker RW
Outcomes for Latin American versus White patients suffering from acute mania in a randomized, double-blind trial comparing olanzapine and haloperidol. J Clin Psychopharmacol. 2007 Apr; 27(2):126-34.
Outcomes for Latin American versus White patients suffering from acute mania in a randomized, double-blind trial comparing olanzapine and haloperidol.
Tohen M, Ng-Mak D, Rajagopalan K, Halpern R, Chuang CC, Loebel A
The primary care companion for CNS disorders
Patient Characteristics Associated With Use of Lurasidone Versus Other Atypical Antipsychotics in Patients With Bipolar Disorder: Analysis From a Claims Database in the United States. Prim Care Companion CNS Disord. 2017 Jun 01; 19(3).
Patient Characteristics Associated With Use of Lurasidone Versus Other Atypical Antipsychotics in Patients With Bipolar Disorder: Analysis From a Claims Database in the United States.
Tohen M, Zarate CA, Hennen J, Khalsa HM, Strakowski SM, Gebre-Medhin P, Salvatore P, Baldessarini RJ
The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry. 2003 Dec; 160(12):2099-107.
The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence.
Brown EB, McElroy SL, Keck PE, Deldar A, Adams DH, Tohen M, Williamson DJ
A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry. 2006 Jul; 67(7):1025-33.
A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression.
Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, Azorin JM, Vieta E, Hardy-Bayle MC, Lawson WB, Emsley RA, Zhang F, Baker RW, Risser RC, Namjoshi MA, Evans AR, Breier A
A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry. 2003 Dec; 60(12):1218-26.
A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania.
Baldessarini RJ, Tondo L, Strombom IM, Dominguez S, Fawcett J, Licinio J, Oquendo MA, Tollefson GD, Valuck RJ, Tohen M
Ecological studies of antidepressant treatment and suicidal risks. Harv Rev Psychiatry. 2007 Jul-Aug; 15(4):133-45.
Ecological studies of antidepressant treatment and suicidal risks.
Extent of comorbidity between mental state and personality disorders. J Pers Disord. 1997; 11(3):242-59.
Extent of comorbidity between mental state and personality disorders.
Heuristic models of comorbidity of axis I and axis II disorders. J Pers Disord. 1997; 11(3):260-9.
Heuristic models of comorbidity of axis I and axis II disorders.
Antipsychotic agents and bipolar disorder. J Clin Psychiatry. 1998; 59 Suppl 1:38-48; discussion 49.
Antipsychotic agents and bipolar disorder.
Stormberg D, Ronningstam E, Gunderson J, Tohen M
Brief communication: pathological narcissism in bipolar disorder patients. J Pers Disord. 1998; 12(2):179-85.
Brief communication: pathological narcissism in bipolar disorder patients.
Hirayasu Y, Shenton ME, Salisbury DF, Dickey CC, Fischer IA, Mazzoni P, Kisler T, Arakaki H, Kwon JS, Anderson JE, Yurgelun-Todd D, Tohen M, McCarley RW
Lower left temporal lobe MRI volumes in patients with first-episode schizophrenia compared with psychotic patients with first-episode affective disorder and normal subjects. Am J Psychiatry. 1998 Oct; 155(10):1384-91.
Lower left temporal lobe MRI volumes in patients with first-episode schizophrenia compared with psychotic patients with first-episode affective disorder and normal subjects.
Shi L, Schuh LM, Trzepacz PT, Huang LX, Namjoshi MA, Tohen M
Improvement of Positive and Negative Syndrome Scale cognitive score associated with olanzapine treatment of acute mania. Curr Med Res Opin. 2004 Sep; 20(9):1371-6.
Improvement of Positive and Negative Syndrome Scale cognitive score associated with olanzapine treatment of acute mania.
Onset of action of antipsychotics in the treatment of mania. Bipolar Disord. 2000 Sep; 2(3 Pt 2):261-8.
Onset of action of antipsychotics in the treatment of mania.
Baldessarini RJ, Bolzani L, Cruz N, Jones PB, Lai M, Lepri B, Perez J, Salvatore P, Tohen M, Tondo L, Vieta E
Onset-age of bipolar disorders at six international sites. J Affect Disord. 2010 Feb; 121(1-2):143-6.
Onset-age of bipolar disorders at six international sites.
Baethge C, Hennen J, Khalsa HM, Salvatore P, Tohen M, Baldessarini RJ
Sequencing of substance use and affective morbidity in 166 first-episode bipolar I disorder patients. Bipolar Disord. 2008 Sep; 10(6):738-41.
Sequencing of substance use and affective morbidity in 166 first-episode bipolar I disorder patients.
Hudson JI, Lipinski JF, Frankenburg FR, Tohen M, Kupfer DJ
Effects of lithium on sleep in mania. Biol Psychiatry. 1989 Mar 01; 25(5):665-8.
Baldessarini RJ, Salvatore P, Khalsa HM, Gebre-Medhin P, Imaz H, González-Pinto A, Perez J, Cruz N, Maggini C, Tohen M
Morbidity in 303 first-episode bipolar I disorder patients. Bipolar Disord. 2010 May; 12(3):264-70.
Morbidity in 303 first-episode bipolar I disorder patients.
Vázquez GH, Kapczinski F, Magalhaes PV, Córdoba R, Lopez Jaramillo C, Rosa AR, Sanchez de Carmona M, Tohen M
Stigma and functioning in patients with bipolar disorder. J Affect Disord. 2011 Apr; 130(1-2):323-7.
Stigma and functioning in patients with bipolar disorder.
Yildiz A, Vieta E, Tohen M, Baldessarini RJ
Factors modifying drug and placebo responses in randomized trials for bipolar mania. Int J Neuropsychopharmacol. 2011 Aug; 14(7):863-75.
Factors modifying drug and placebo responses in randomized trials for bipolar mania.
Medications for bipolar disorders: a review of their therapeutic and pharmacological differences. Part I: from antimanics to euthymics. Actas Esp Psiquiatr. 2004 Jan; 32 Suppl 1:3-17.
Medications for bipolar disorders: a review of their therapeutic and pharmacological differences. Part I: from antimanics to euthymics.
Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G
One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994 Oct; 151(10):1409-16.
One hundred years of schizophrenia: a meta-analysis of the outcome literature.
McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A
Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry. 2006 May; 163(5):790-9.
Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis.
Perlis RH, Baker RW, Zarate CA, Brown EB, Schuh LM, Jamal HH, Tohen M
Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial. J Clin Psychiatry. 2006 Nov; 67(11):1747-53.
Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial.
Berk M, Malhi GS, Cahill C, Carman AC, Hadzi-Pavlovic D, Hawkins MT, Tohen M, Mitchell PB
The Bipolar Depression Rating Scale (BDRS): its development, validation and utility. Bipolar Disord. 2007 Sep; 9(6):571-9.
The Bipolar Depression Rating Scale (BDRS): its development, validation and utility.
Berk M, Ng F, Wang WV, Tohen M, Lubman DI, Vieta E, Dodd S
Going up in smoke: tobacco smoking is associated with worse treatment outcomes in mania. J Affect Disord. 2008 Sep; 110(1-2):126-34.
Going up in smoke: tobacco smoking is associated with worse treatment outcomes in mania.
Clozapine in severe mood disorders. J Clin Psychiatry. 1995 Sep; 56(9):411-7.
Zarate CA, Tohen M, Banov MD, Weiss MK, Cole JO
Is clozapine a mood stabilizer? J Clin Psychiatry. 1995 Mar; 56(3):108-12.
Strakowski SM, Tohen M, Flaum M, Amador X
Substance abuse in psychotic disorders: associations with affective syndromes. DSM-IV Field Trial Work Group. Schizophr Res. 1994 Dec; 14(1):73-81.
Substance abuse in psychotic disorders: associations with affective syndromes. DSM-IV Field Trial Work Group.
Zarate CA, Baldessarini RJ, Siegel AJ, Nakamura A, McDonald J, Muir-Hutchinson LA, Cherkerzian T, Tohen M
Risperidone in the elderly: a pharmacoepidemiologic study. J Clin Psychiatry. 1997 Jul; 58(7):311-7.
Risperidone in the elderly: a pharmacoepidemiologic study.
Olsen BT, Ganocy SJ, Bitter SM, Findling RL, Case M, Chang K, Tohen M, DelBello MP
Health-related quality of life as measured by the child health questionnaire in adolescents with bipolar disorder treated with olanzapine. Compr Psychiatry. 2012 Oct; 53(7):1000-5.
Health-related quality of life as measured by the child health questionnaire in adolescents with bipolar disorder treated with olanzapine.
Karagianis J, Rosenbluth M, Tohen M, Ascher-Svanum H, Treuer T, de Lima MS, Citrome L
Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools. Curr Med Res Opin. 2007 Oct; 23(10):2551-7.
Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools.
Carlson GA, Findling RL, Post RM, Birmaher B, Blumberg HP, Correll C, DelBello MP, Fristad M, Frazier J, Hammen C, Hinshaw SP, Kowatch R, Leibenluft E, Meyer SE, Pavuluri MN, Wagner KD, Tohen M
AACAP 2006 Research Forum--Advancing research in early-onset bipolar disorder: barriers and suggestions. J Child Adolesc Psychopharmacol. 2009 Feb; 19(1):3-12.
AACAP 2006 Research Forum--Advancing research in early-onset bipolar disorder: barriers and suggestions.
Tamayo JM, Sutton VK, Mattei MA, Diaz B, Jamal HH, Vieta E, Zarate CA, Fumero I, Tohen M
Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico. J Clin Psychopharmacol. 2009 Aug; 29(4):358-61.
Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico.
Houston JP, Tohen M, Degenhardt EK, Jamal HH, Liu LL, Ketter TA
Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study. J Clin Psychiatry. 2009 Nov; 70(11):1540-7.
Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study.
Tohen M, Sniadecki J, Sutton VK, Degenhardt EK, Karagianis JL, Sagman D, Jacobson JG
Number needed to treat or harm analyses of olanzapine for maintenance treatment of bipolar disorder. J Clin Psychopharmacol. 2009 Dec; 29(6):520-8.
Number needed to treat or harm analyses of olanzapine for maintenance treatment of bipolar disorder.
Kemp DE, Ganocy SJ, Brecher M, Carlson BX, Edwards S, Eudicone JM, Evoniuk G, Jansen W, Leon AC, Minkwitz M, Pikalov A, Stassen HH, Szegedi A, Tohen M, Van Willigenburg AP, Calabrese JR
Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. J Affect Disord. 2011 Apr; 130(1-2):171-9.
Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression.
Safety and efficacy of olanzapine monotherapy and olanzapine with a mood stabilizer in 18-week treatment of manic/mixed episodes for Japanese patients with bipolar I disorder. Curr Med Res Opin. 2012 May; 28(5):701-13.
Safety and efficacy of olanzapine monotherapy and olanzapine with a mood stabilizer in 18-week treatment of manic/mixed episodes for Japanese patients with bipolar I disorder.
Köhler-Forsberg O, Madsen T, Behrendt-Møller I, Sylvia L, Bowden CL, Gao K, Bobo WV, Trivedi MH, Calabrese JR, Thase M, Shelton RC, McInnis M, Tohen M, Ketter TA, Friedman ES, Deckersbach T, McElroy SL, Reilly-Harrington NA, Nierenberg AA
Trajectories of suicidal ideation over 6 months among 482 outpatients with bipolar disorder. J Affect Disord. 2017 12 01; 223:146-152.
Trajectories of suicidal ideation over 6 months among 482 outpatients with bipolar disorder.
Corrigendum to bipolar mixed features - Results from the comparative effectiveness for bipolar disorder (Bipolar CHOICE) study [Journal of Affective Disorders 217 (2017) 183-189]. J Affect Disord. 2018 01 01; 225:775-777.
Corrigendum to bipolar mixed features - Results from the comparative effectiveness for bipolar disorder (Bipolar CHOICE) study [Journal of Affective Disorders 217 (2017) 183-189].
Berk M, Brnabic A, Dodd S, Kelin K, Tohen M, Malhi GS, Berk L, Conus P, McGorry PD
Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. Bipolar Disord. 2011 Feb; 13(1):87-98.
Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention.
Sylvia LG, Chang WC, Kamali M, Tohen M, Kinrys G, Deckersbach T, Calabrese JR, Thase ME, Reilly-Harrington N, Bobo WV, Kocsis JH, McInnis MG, Bowden CL, Ketter TA, Friedman ES, Shelton RC, McElroy SL, Gao K, Rabideau DJ, Nierenberg AA
Sleep disturbance may impact treatment outcome in bipolar disorder: A preliminary investigation in the context of a large comparative effectiveness trial. J Affect Disord. 2018 01 01; 225:563-568.
Sleep disturbance may impact treatment outcome in bipolar disorder: A preliminary investigation in the context of a large comparative effectiveness trial.
Tohen M, Khalsa HK, Salvatore P, Vieta E, Ravichandran C, Baldessarini RJ
Two-year outcomes in first-episode psychotic depression the McLean-Harvard First-Episode Project. J Affect Disord. 2012 Jan; 136(1-2):1-8.
Two-year outcomes in first-episode psychotic depression the McLean-Harvard First-Episode Project.
Stoll AL, Banov M, Kolbrener M, Mayer PV, Tohen M, Strakowski SM, Castillo J, Suppes T, Cohen BM
Neurologic factors predict a favorable valproate response in bipolar and schizoaffective disorders. J Clin Psychopharmacol. 1994 Oct; 14(5):311-3.
Neurologic factors predict a favorable valproate response in bipolar and schizoaffective disorders.
Maintenance treatment in bipolar disorder. Arch Gen Psychiatry. 2000 May; 57(5):490-2.
Maintenance treatment in bipolar disorder.
The need to change from a phenomenological to a target engagement approach. Bipolar Disord. 2017 09; 19(6):513-514.
The need to change from a phenomenological to a target engagement approach.
Nestsiarovich A, Hurwitz NG, Nelson SJ, Crisanti AS, Kerner B, Kuntz MJ, Smith AN, Volesky E, Schroeter QL, DeShaw JL, Young SS, Obenchain RL, Krall RL, Jordan K, Fawcett J, Tohen M, Perkins DJ, Lambert CG
Systemic challenges in bipolar disorder management: A patient-centered approach. Bipolar Disord. 2017 12; 19(8):676-688.
Systemic challenges in bipolar disorder management: A patient-centered approach.
Frazier JA, Biederman J, Tohen M, Feldman PD, Jacobs TG, Toma V, Rater MA, Tarazi RA, Kim GS, Garfield SB, Sohma M, Gonzalez-Heydrich J, Risser RC, Nowlin ZM
A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol. 2001; 11(3):239-50.
A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder.
Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 2003 Aug; 160(8):1396-404.
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.
Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003 Nov; 60(11):1079-88.
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.
Shi L, Namjoshi MA, Swindle R, Yu X, Risser R, Baker RW, Tohen M
Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial. Clin Ther. 2004 Jan; 26(1):125-34.
Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial.
Baethge C, Baldessarini RJ, Khalsa HM, Hennen J, Salvatore P, Tohen M
Substance abuse in first-episode bipolar I disorder: indications for early intervention. Am J Psychiatry. 2005 May; 162(5):1008-10.
Substance abuse in first-episode bipolar I disorder: indications for early intervention.
Xiao L, Ganocy SJ, Findling RL, Chang K, DelBello MP, Kane JM, Tohen M, Xiang YT, Correll CU
Baseline Characteristics and Early Response at Week 1 Predict Treatment Outcome in Adolescents With Bipolar Manic or Mixed Episode Treated With Olanzapine: Results From a 3-Week, Randomized, Placebo-Controlled Trial. J Clin Psychiatry. 2017 Nov/Dec; 78(9):e1158-e1166.
Baseline Characteristics and Early Response at Week 1 Predict Treatment Outcome in Adolescents With Bipolar Manic or Mixed Episode Treated With Olanzapine: Results From a 3-Week, Randomized, Placebo-Controlled Trial.
Treatment Guidelines in Bipolar Disorders and the Importance of Proper Clinical Trial Design. Int J Neuropsychopharmacol. 2017 02 01; 20(2):95-97.
Treatment Guidelines in Bipolar Disorders and the Importance of Proper Clinical Trial Design.
Vieta E, Berk M, Wang W, Colom F, Tohen M, Baldessarini RJ
Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients. J Affect Disord. 2009 Dec; 119(1-3):22-7.
Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients.
Tohen M, Vieta E, Gonzalez-Pinto A, Reed C, Lin D
Baseline characteristics and outcomes in patients with first episode or multiple episodes of acute mania. J Clin Psychiatry. 2010 Mar; 71(3):255-61.
Baseline characteristics and outcomes in patients with first episode or multiple episodes of acute mania.
Benazzi F, Berk M, Frye MA, Wang W, Barraco A, Tohen M
Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis. J Clin Psychiatry. 2009 Oct; 70(10):1424-31.
Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.
Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Tohen M
Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry. 1997 Jan; 54(1):49-55.
Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment.
Banov MD, Zarate CA, Tohen M, Scialabba D, Wines JD, Kolbrener M, Kim JW, Cole JO
Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry. 1994 Jul; 55(7):295-300.
Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up.
Strakowski SM, Tohen M, Stoll AL, Faedda GL, Mayer PV, Kolbrener ML, Goodwin DC
Comorbidity in psychosis at first hospitalization. Am J Psychiatry. 1993 May; 150(5):752-7.
Comorbidity in psychosis at first hospitalization.
Sanger TM, Grundy SL, Gibson PJ, Namjoshi MA, Greaney MG, Tohen MF
Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. J Clin Psychiatry. 2001 Apr; 62(4):273-81.
Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study.
Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J, Koch M, Rizk R, Walker D, Tran P, Breier A
A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol. 2001 Aug; 21(4):389-97.
A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania.
Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J, Miller TJ, Hawkins KA, Marquez E, Lindborg SR, Tohen M, McGlashan TH
Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry. 2003 Aug 15; 54(4):453-64.
Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome.
Chengappa KN, Hennen J, Baldessarini RJ, Kupfer DJ, Yatham LN, Gershon S, Baker RW, Tohen M
Recovery and functional outcomes following olanzapine treatment for bipolar I mania. Bipolar Disord. 2005 Feb; 7(1):68-76.
Recovery and functional outcomes following olanzapine treatment for bipolar I mania.
Salvatore P, Khalsa HM, Hennen J, Tohen M, Yurgelun-Todd D, Casolari F, Depanfilis C, Maggini C, Baldessarini RJ
Psychopathology factors in first-episode affective and non-affective psychotic disorders. J Psychiatr Res. 2007 Nov; 41(9):724-36.
Psychopathology factors in first-episode affective and non-affective psychotic disorders.
Vieta E, Reinares M, Corbella B, Benabarre A, Gilaberte I, Colom F, Martínez-Arán A, Gastó C, Tohen M
Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder. J Clin Psychopharmacol. 2001 Oct; 21(5):469-73.
Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder.
Tohen M, Zhang F, Keck PE, Feldman PD, Risser RC, Tran PV, Breier A
Olanzapine versus haloperidol in schizoaffective disorder, bipolar type. J Affect Disord. 2001 Dec; 67(1-3):133-40.
Olanzapine versus haloperidol in schizoaffective disorder, bipolar type.
Goldstein JM, Cohen LS, Horton NJ, Lee H, Andersen S, Tohen M, Crawford A, Tollefson G
Sex differences in clinical response to olanzapine compared with haloperidol. Psychiatry Res. 2002 May 15; 110(1):27-37.
Sex differences in clinical response to olanzapine compared with haloperidol.
McEvoy JP, Johnson J, Perkins D, Lieberman JA, Hamer RM, Keefe RS, Tohen M, Glick ID, Sharma T
Insight in first-episode psychosis. Psychol Med. 2006 Oct; 36(10):1385-93.
Corya SA, Perlis RH, Keck PE, Lin DY, Case MG, Williamson DJ, Tohen MF
A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. J Clin Psychiatry. 2006 May; 67(5):798-806.
A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression.
Tohen M, Bowden CL, Smulevich AB, Bergstrom R, Quinlan T, Osuntokun O, Wang WV, Oliff HS, Martenyi F, Kryzhanovskaya LA, Greil W
Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. Br J Psychiatry. 2008 Feb; 192(2):135-43.
Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes.
Commentary on N. Ghaemi's "Hippocratic Psychopharmacology of Bipolar Disorder" Maintenance Treatment in Bipolar Disorder. Psychiatry (Edgmont). 2006 Jun; 3(6):43-5.
Commentary on N. Ghaemi's "Hippocratic Psychopharmacology of Bipolar Disorder" Maintenance Treatment in Bipolar Disorder.
Author's reply: To PMID 22918966. Br J Psychiatry. 2013 Feb; 202:153-4.
Lukasiewicz M, Gerard S, Besnard A, Falissard B, Perrin E, Sapin H, Tohen M, Reed C, Azorin JM
International journal of methods in psychiatric research
Young Mania Rating Scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort. Int J Methods Psychiatr Res. 2013 Mar; 22(1):46-58.
Young Mania Rating Scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort.
Suppes T, Baldessarini RJ, Faedda GL, Tohen M
Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry. 1991 Dec; 48(12):1082-8.
Risk of recurrence following discontinuation of lithium treatment in bipolar disorder.
Rothschild AJ, Williamson DJ, Tohen MF, Schatzberg A, Andersen SW, Van Campen LE, Sanger TM, Tollefson GD
A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol. 2004 Aug; 24(4):365-73.
A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features.
Namjoshi MA, Risser R, Shi L, Tohen M, Breier A
Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid. J Affect Disord. 2004 Sep; 81(3):223-9.
Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid.
Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Rock SL, Woolson S, Tohen M, Tollefson GD, Sanger TM, Lieberman JA
Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol Psychiatry. 2006 Jan 15; 59(2):97-105.
Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis.
Tohen M, Waternaux CM, Tsuang MT, Hunt AT
Four-year follow-up of twenty-four first-episode manic patients. J Affect Disord. 1990 Jun; 19(2):79-86.
Four-year follow-up of twenty-four first-episode manic patients.
Caldieraro MA, Walsh S, Deckersbach T, Bobo WV, Gao K, Ketter TA, Shelton RC, Reilly-Harrington NA, Tohen M, Calabrese JR, Thase ME, Kocsis JH, Sylvia LG, Nierenberg AA
Decreased activation and subsyndromal manic symptoms predict lower remission rates in bipolar depression. Aust N Z J Psychiatry. 2018 10; 52(10):994-1002.
Decreased activation and subsyndromal manic symptoms predict lower remission rates in bipolar depression.
Clinical trials in bipolar mania: implications in study design and drug development. Arch Gen Psychiatry. 2008 Mar; 65(3):252-3.
Clinical trials in bipolar mania: implications in study design and drug development.
Namjoshi MA, Rajamannar G, Jacobs T, Sanger TM, Risser R, Tohen MF, Breier A, Keck PE
Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania. Results from a randomized controlled trial. J Affect Disord. 2002 May; 69(1-3):109-18.
Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania. Results from a randomized controlled trial.
Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, Altshuler L, Zajecka J, Schuh LM, Risser RC, Brown E, Baker RW
Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry. 2003 Jul; 160(7):1263-71.
Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study.
Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Lewine RR, Yurgelun-Todd DA, Gur RC, Tohen M, Tollefson GD, Sanger TM, Lieberman JA
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry. 2004 Jun; 161(6):985-95.
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
Zhu B, Tunis SL, Zhao Z, Baker RW, Lage MJ, Shi L, Tohen M
Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial. Curr Med Res Opin. 2005 Apr; 21(4):555-64.
Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial.
Kupfer DJ, Angst J, Berk M, Dickerson F, Frangou S, Frank E, Goldstein BI, Harvey A, Laghrissi-Thode F, Leboyer M, Ostacher MJ, Sibille E, Strakowski SM, Suppes T, Tohen M, Yolken RH, Young LT, Zarate CA
Annals of the New York Academy of Sciences
Advances in bipolar disorder: selected sessions from the 2011 International Conference on Bipolar Disorder. Ann N Y Acad Sci. 2011 Dec; 1242:1-25.
Advances in bipolar disorder: selected sessions from the 2011 International Conference on Bipolar Disorder.
Kando JC, Tohen M, Castillo J, Zarate CA
The use of valproate in an elderly population with affective symptoms. J Clin Psychiatry. 1996 Jun; 57(6):238-40.
The use of valproate in an elderly population with affective symptoms.
Köhler-Forsberg O, Sylvia L, Deckersbach T, Ostacher MJ, McInnis M, Iosifescu D, Bowden C, McElroy S, Calabrese J, Thase M, Shelton RC, Tohen M, Kocsis J, Friedman E, Ketter T, Nierenberg AA
Clinically relevant and simple immune system measure is related to symptom burden in bipolar disorder. Acta Neuropsychiatr. 2018 Oct; 30(5):297-305.
Clinically relevant and simple immune system measure is related to symptom burden in bipolar disorder.
Kemp DE, Johnson E, Wang WV, Tohen M, Calabrese JR
Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidone. J Clin Psychiatry. 2011 Sep; 72(9):1236-41.
Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidone.
Circadian Rhythm and the Prediction of Relapse in Bipolar Disorder. J Clin Psychiatry. 2018 Jan/Feb; 79(1).
Circadian Rhythm and the Prediction of Relapse in Bipolar Disorder.
Montoya A, Tohen M, Vieta E, Casillas M, Chacón F, Polavieja P, Gilaberte I
Functioning and symptomatic outcomes in patients with bipolar I disorder in syndromal remission: a 1-year, prospective, observational cohort study. J Affect Disord. 2010 Dec; 127(1-3):50-7.
Functioning and symptomatic outcomes in patients with bipolar I disorder in syndromal remission: a 1-year, prospective, observational cohort study.
Greenfield SF, Strakowski SM, Tohen M, Batson SC, Kolbrener ML
Childhood abuse in first-episode psychosis. Br J Psychiatry. 1994 Jun; 164(6):831-4.
Childhood abuse in first-episode psychosis.
Severity of symptoms in mania-clinical guidelines and study design implications. Bipolar Disord. 2018 03; 20(2):171-172.
Severity of symptoms in mania-clinical guidelines and study design implications.
Caldieraro MA, Dufour S, Sylvia LG, Gao K, Ketter TA, Bobo WV, Walsh S, Janos J, Tohen M, Reilly-Harrington NA, McElroy SL, Shelton RC, Bowden CL, Deckersbach T, Nierenberg AA
Treatment outcomes of acute bipolar depressive episode with psychosis. Depress Anxiety. 2018 05; 35(5):402-410.
Treatment outcomes of acute bipolar depressive episode with psychosis.
McLean-Harvard International First-Episode Project: two-year stability of ICD-10 diagnoses in 500 first-episode psychotic disorder patients. J Clin Psychiatry. 2011 Feb; 72(2):183-93.
McLean-Harvard International First-Episode Project: two-year stability of ICD-10 diagnoses in 500 first-episode psychotic disorder patients.
Tohen M, McDonnell DP, Case M, Kanba S, Ha K, Fang YR, Katagiri H, Gomez JC
Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. Br J Psychiatry. 2012 Nov; 201(5):376-82.
Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression.
Tohen M, Kryzhanovskaya L, Carlson G, Delbello M, Wozniak J, Kowatch R, Wagner K, Findling R, Lin D, Robertson-Plouch C, Xu W, Dittmann RW, Biederman J
Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry. 2007 Oct; 164(10):1547-56.
Olanzapine versus placebo in the treatment of adolescents with bipolar mania.
Hoffman RE, Woods SW, Hawkins KA, Pittman B, Tohen M, Preda A, Breier A, Glist J, Addington J, Perkins DO, McGlashan TH
Extracting spurious messages from noise and risk of schizophrenia-spectrum disorders in a prodromal population. Br J Psychiatry. 2007 Oct; 191:355-6.
Extracting spurious messages from noise and risk of schizophrenia-spectrum disorders in a prodromal population.
Vieta E, Salagre E, Grande I, Carvalho AF, Fernandes BS, Berk M, Birmaher B, Tohen M, Suppes T
Early Intervention in Bipolar Disorder. Am J Psychiatry. 2018 05 01; 175(5):411-426.
Stoll AL, Tohen M, Baldessarini RJ, Goodwin DC, Stein S, Katz S, Geenens D, Swinson RP, Goethe JW, McGlashan T
Shifts in diagnostic frequencies of schizophrenia and major affective disorders at six North American psychiatric hospitals, 1972-1988. Am J Psychiatry. 1993 Nov; 150(11):1668-73.
Shifts in diagnostic frequencies of schizophrenia and major affective disorders at six North American psychiatric hospitals, 1972-1988.
Strakowski SM, Woods BT, Tohen M, Wilson DR, Douglass AW, Stoll AL
MRI subcortical signal hyperintensities in mania at first hospitalization. Biol Psychiatry. 1993 Feb 01; 33(3):204-6.
MRI subcortical signal hyperintensities in mania at first hospitalization.
Tohen M, Zarate CA, Centorrino F, Hegarty JI, Froeschl M, Zarate SB
Risperidone in the treatment of mania. J Clin Psychiatry. 1996 Jun; 57(6):249-53.
Baldessarini RJ, Vieta E, Calabrese JR, Tohen M, Bowden CL
Bipolar depression: overview and commentary. Harv Rev Psychiatry. 2010 May-Jun; 18(3):143-57.
Bipolar depression: overview and commentary.
International review of psychiatry (Abingdon, England)
Current status and future perspectives for psychiatry/mental health research in Latin America. Int Rev Psychiatry. 2010; 22(4):382-93.
Current status and future perspectives for psychiatry/mental health research in Latin America.
Baldessarini RJ, Tondo L, Vazquez GH, Undurraga J, Bolzani L, Yildiz A, Khalsa HM, Lai M, Lepri B, Lolich M, Maffei PM, Salvatore P, Faedda GL, Vieta E, Tohen M
Age at onset versus family history and clinical outcomes in 1,665 international bipolar-I disorder patients. World Psychiatry. 2012 Feb; 11(1):40-6.
Age at onset versus family history and clinical outcomes in 1,665 international bipolar-I disorder patients.
Thyroid function tests in first-episode bipolar disorder manic and mixed types. Biol Psychiatry. 1997 Aug 15; 42(4):302-4.
Thyroid function tests in first-episode bipolar disorder manic and mixed types.
Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY
A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001 Jan; 158(1):131-4.
A novel augmentation strategy for treating resistant major depression.
Kwon JS, Shenton ME, Hirayasu Y, Salisbury DF, Fischer IA, Dickey CC, Yurgelun-Todd D, Tohen M, Kikinis R, Jolesz FA, McCarley RW
MRI study of cavum septi pellucidi in schizophrenia, affective disorder, and schizotypal personality disorder. Am J Psychiatry. 1998 Apr; 155(4):509-15.
MRI study of cavum septi pellucidi in schizophrenia, affective disorder, and schizotypal personality disorder.
Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, McEvoy JP, Strakowski SM, Sharma T, Kahn RS, Gur RE, Tollefson GD, Lieberman JA
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry. 2005 Dec; 187:537-43.
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol.
Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R, Baker RW, Chou JC, Bowden CL
Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry. 2006 Feb; 163(2):247-56.
Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine.
Zarate CA, Tohen M, Narendran R, Tomassini EC, McDonald J, Sederer M, Madrid AR
The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: a pharmacoepidemiology study. J Clin Psychiatry. 1999 Apr; 60(4):232-6.
The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: a pharmacoepidemiology study.
Tohen M, Hennen J, Zarate CM, Baldessarini RJ, Strakowski SM, Stoll AL, Faedda GL, Suppes T, Gebre-Medhin P, Cohen BM
Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry. 2000 Feb; 157(2):220-8.
Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features.
Strakowski SM, Faedda GL, Tohen M, Goodwin DC, Stoll AL
Possible affective-state dependence of the Tridimensional Personality Questionnaire in first-episode psychosis. Psychiatry Res. 1992 Mar; 41(3):215-26.
Possible affective-state dependence of the Tridimensional Personality Questionnaire in first-episode psychosis.
Gonzalez-Pinto A, Tohen M, Lalaguna B, Pérez-Heredia JL, Fernandez-Corres B, Gutierrez M, Micó JA
Treatment of bipolar I rapid cycling patients during dysphoric mania with olanzapine. J Clin Psychopharmacol. 2002 Oct; 22(5):450-4.
Treatment of bipolar I rapid cycling patients during dysphoric mania with olanzapine.
Baker RW, Tohen M, Fawcett J, Risser RC, Schuh LM, Brown E, Stauffer VL, Shao L, Tollefson GD
Acute dysphoric mania: treatment response to olanzapine versus placebo. J Clin Psychopharmacol. 2003 Apr; 23(2):132-7.
Acute dysphoric mania: treatment response to olanzapine versus placebo.